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Abstracts 1
A. Abstracts 
A.1 Zusammenfassung 
Das Epstein-Barr-Virus (EBV) ist mit einer Vielzahl maligner Erkrankungen assoziiert. Nach 
Primärinfektion persistiert das Virus lebenslang im Wirt. Während dieser Phase der klinischen 
Viruslatenz wird die Virusproduktion zyklisch in latent infizierten B-Zellen reaktiviert. Bei 
ausbleibender immunologischer Kontrolle, zum Beispiel im Rahmen einer Organ- oder 
Stammzell-Transplantation, kann die Infektion disseminieren und eine lymphoproliferative 
Erkrankung auslösen. Durch den adoptiven Transfer von EBV-spezifischen T-Zellen, die 
durch wiederholte Stimulation mit autologen lymphoblastoiden Zelllinien (LCL) in vitro 
generiert werden, können lymphoproliferative Erkrankungen nach Transplantationen (PTLD) 
geheilt werden. Allerdings ist die Herstellung solcher T-Zell-Vakzine noch so aufwendig und 
langwierig, dass sie derzeit nur prospektiv ausgewählten Risiko-Patienten zur Verfügung 
stehen. Von einer Identifikation der relevanten T-Zell-Antigene des EBV wird eine 
Verbesserung der Therapieansätze erwartet, in Richtung breiter Anwendbarkeit bei Patienten 
mit drohender oder manifester PTLD. Während die EBV-spezifische Antwort von CD8+ T-
Zellen bereits gut charakterisiert worden war, waren die Zielstrukturen der EBV-spezifischen 
CD4+ T-Zell-Antwort zu Beginn der vorliegenden Arbeit weitgehend unbekannt. 
Ziel der vorliegenden Arbeit war es deshalb, die Spezifität und Breite der EBV-spezifischen 
Antwort von CD4+ Helfer-T-Zellen zu untersuchen. Zu diesem Zweck wurden zwei parallele 
Ansätze gewählt. Zum einen wurden von 23 verschiedenen, EBV-positiven und –negativen 
Spendern LCL angelegt, durch repetitive Stimulation mit diesen LCL autologe, CD4+ T-
Zelllinien und –Klone generiert und deren Spezifität mit Hilfe von Protein-gepulsten 
Zielzellen näher charakterisiert. Zum anderen wurde mit Hilfe von Protein-gepulsten 
peripheren mononukleären Blutzellen (PBMC) nach EBV-spezifischen CD4+ Helfer-T-
Zellvorläufern bei gesunden, EBV-positiven oder -negativen Probanden gesucht, und so die 
Breite der Immunantwort charakterisiert. 
Zusammenfassend reagierten die CD4+ T-Zellen EBV-negativer Spender nur mäßig auf LCL 
und wiesen keine EBV-Spezifität auf. Dagegen waren alle von gesunden EBV-positiven 
Spendern etablierten CD4+ T-Zelllinien EBV-spezifisch. Die CD4+ T-Zelllinien von frisch 
infizierten Patienten mit Symptomen einer typischen Infektiösen Mononukleose (IM) waren 
je zur Hälfte EBV-spezifisch oder autoreaktiv. Überraschenderweise erkannten die EBV-
spezifischen T-Zelllinien nicht, wie bisher allgemein angenommen, die in allen LCL 
exprimierten Latenzgene, sondern verschiedene Proteine des lytischen Zyklus von EBV. 
Abstracts 2
Letztere waren vornehmlich Strukturproteine des Viruspartikels, mit einer dominanten Rolle 
des Tegument-Proteins BNRF1.  
Die Frequenzanalyse von EBV-spezifischen Helfer-T-Zellvorläufern bestätigte eine zentrale 
Bedeutung von CD4+ T-Zellen mit Spezifität für verschiedene Antigene des lytischen Zyklus 
für das EBV-spezifische immunologische Gedächtnis. Bemerkenswerterweise erkannten die 
Viruspartikel-spezifischen CD4+ T-Zellen die EBV-positiven Zellen zum einen direkt und 
zum anderen unabhängig von der Expression von Proteinen des lytischen Zyklus. Dieser 
bystander-Effekt konnte durch einen effizienten, Rezeptor-vermittelten Transfer von Antigen 
zwischen Viruspartikel freisetzenden und Nachbarzellen erklärt werden. Von großer 
therapeutischer Bedeutung war die Beobachtung, dass die T-Zell-Erkennung von EBV-
Partikel-aufnehmenden Zellen bereits bei Beladung mit nur einem Viruspartikel pro Zelle und 
noch vor Etablierung von Viruslatenz oder –Produktion stattfand. Klinisch bedeutsam war 
darüber hinaus der Befund, dass die Viruspartikel-spezifischen CD4+ T-Zellen nach Antigen-
Kontakt über Sekretion von Perforin und Granzym B zytolytisch auf ihre Zielzelle wirkten 
und so die Proliferation und das Auswachsen von LCL aus frisch mit EBV infizierten B-
Zellen verhindern konnten.  
Diese Ergebnisse weisen erstmals auf eine zentrale Rolle von Virushüllproteinen in der MHC 
Klasse II-restringierten immunologischen Kontrolle von EBV-Infektionen hin und damit auf 
ihre hohe Relevanz für neue immuntherapeutische Ansätze. Die Befunde sind möglicherweise 
nicht nur für die Therapie von EBV-assoziierten Erkrankungen interessant, sondern könnten 
darüberhinaus im Kontext von Infektionen mit anderen Viren wichtig sein, die eine Virushülle 
tragen und über diese MHC Klass II-positive Zellen infizieren. 
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A.2 Summary 
The Epstein-Barr virus (EBV) is associated with a number of human malignancies. Following 
primary infection, the virus persists lifelong in the infected host by latently infecting B cells 
and occasional cycles of reactivation, virus production and re-infection. Adoptively 
transferred EBV-specific T cells, generated by repeated stimulation with autologous 
lymphoblastoid cell lines (LCL) in vitro, are able to cure post-transplant lymphoproliferative 
disease (PTLD). However, the generation of these vaccines is labor and cost intensive 
precluding their general availability for all patients at risk. Novel insights into the 
mechanisms of protective antiviral immunity is expected to provide a better understanding of 
the pathogenesis of EBV-associated diseases and to facilitate the development of novel and 
generally available immunotherapeutic options.  
The aim of this work was to assess specificity and breadth of the EBV-specific T helper cell 
response, using two different experimental strategies.  
To define specificity, LCL-stimulated CD4+ T cell lines were established from 23 EBV-
negative and -positive donors. The T cell lines generated from EBV-negative donors 
responded poorly against LCL and failed to show EBV-specificity. By contrast, all T cell 
lines established from healthy virus carriers were EBV-specific. Half of the lines from acutely 
EBV-infected patients with infectious mononucleosis (IM) were also EBV-specific, while the 
other half recognized EBV-positive and EBV-negative target cells. Unexpectedly, the EBV-
specific T cell lines did not recognize latent antigens of EBV expressed in all LCL. Instead, 
these lines were specific for lytic cycle antigens predominantly derived from virion proteins. 
Several of the T cell lines recognized BNRF1, a viral tegument protein. Most T cell lines, 
however, recognized different virion antigens, suggesting that the family of virion proteins 
forms the immunodominant targets of the EBV-specific T helper cell response.  
Studies on the breadth of the EBV-specific T helper response demonstrated that all healthy 
virus carriers maintain CD4+ T cell memory to lytic cycle antigens. T cells specific for virion 
antigens recognized EBV-positive cells directly and, surprisingly, a much higher percentage 
of target cells than those expressing lytic cycle proteins. Antigen was efficiently transferred to 
bystander B cells by receptor-mediated uptake of released virions, resulting in recognition of 
target cells incubated with less than one virion per cell. T cell recognition did not require 
productive infection and occurred early after virus entry before latency was established. By 
secreting perforin and granzyme B upon antigen recognition, virion-specific T helper cells 
inhibited proliferation of LCLs and suppressed the outgrowth of LCLs following infection of 
primary B cells with EBV.  
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These results established a novel role for virion-specific T helper cells in the control of EBV 
infection, and identify virion proteins as important immune targets. The findings have 
implications for the treatment of diseases associated with EBV and potentially other coated 
viruses infecting MHC class II-positive cells.  
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B. Abbreviations 
µg     microgram 
µl     microliter 
APC     antigen presenting cell 
BATDA bis(acetomethyl) 2,2´:6´,2´´–tetrapyridine-
6,6”dicarboxylate 
BL      Burkitt’s lymphoma 
cDNA     complementary deoxyribonucleic acid 
CO2     carbondioxide 
DAB     diaminobenzidine 
DC     dendritic cells 
DMSO    dimethylsulfoxide 
DNA     deoxyribonucleic acid 
E.coli     Escherichia coli 
EBER     Epstein-Barr virus encoded RNA 
EBNA     Epstein-Barr virus nuclear antigen 
EBV     Epstein-Barr virus 
EDTA     ethylenediaminetetraacetic acid 
ELISA     enzyme-linked immunosorbent assay 
ELISPOT    enzyme-linked immunospot assay 
FACS     fluorescence-activated cell sorting 
FCS     fetal calf serum 
FITC     fluorescein isothiocyanate 
X g     times the relative centrifuge force (gravity) 
g     gram 
GM-CSF    granulocyte-monocyte colony-stimulating-factor 
Gy     Gray 
h     hour(s) 
HIV     human immunodeficiency virus 
HLA     human leucocyte antigen 
IFN-γ     interferon gamma 
Ig     immunoglobulin 
IL     interleukin 
IM      infectious mononucleosis 
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IPTG      isopropyl-1-thio-β-D-galactoside 
kb     kilobases 
l     liter 
LCL     lymphoblastoid cell line 
LMP     latent membrane protein 
M     molar 
mg     milligram 
MHC     major histocompatibility complex 
min     minute(s) 
ml     milliliter 
mm     millimeter 
mM     millimolar 
mRNA    messenger ribonucleic acid 
ng     nanogram 
NK cell    natural killer cell 
OD     optical density 
ORF     open reading frame 
PBMC     peripheral blood mononuclear cells 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PE      phycoerythrin 
PG-E2     prostaglandin E2 
PHA     phytohemaglutinin 
PI     propidium iodide 
PTLD     post-transplantation lymphoproliferative disease 
RNA     ribonucleic acid 
rpm     rotations per minute 
RT-PCR    reverse transcription-polymerase chain reaction 
SOT     solid organ transplantation 
TAE     Tris acetate-EDTA 
TE     Tris-EDTA 
TGF-β     Transforming growth factor-beta 
Th     T helper 
TNF-α     tumor necrosis factor-alpha 
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TR      terminal repeat 
Tween 20    polyoxyethylene sorbitane monolaurate 
U     unit 
VCA     viral capsid antigen 
X-gal     5-Bromo-4-Chloro-3-Indoyl-b-D-galactopyranosid 
ºC     degree centigrade 
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1. Introduction 
 
1.1 The Epstein-Barr virus 
In the 1950s, the Irish missionary surgeon Dennis Burkitt observed and treated African 
children with previously undescribed extranodal lymphomas, known today as Burkitt’s 
lymphoma (BL) (Burkitt, 1958). The high incidence of this tumor in regions of equatorial 
Africa led Burkitt to postulate that an infectious agent was involved in the tumor’s etiology, 
prompting attempts by Tony Epstein to identify agents associated with the disease. Epstein 
(and his co-workers including Yvonne Barr) identified in 1964 particles of herpesviral 
morphology in the cell line EB1 that they had successfully established from a BL (Epstein et 
al., 1964). This virus proved to be biologically and antigenically distinct from other members 
of the human herpesvirus family, thereby identifying the Epstein-Barr virus (EBV) as the first 
human tumor virus. 
 
1.1.1 Classification and structure  
EBV is the prototype of the gamma-herpesviridae subfamily of herpesviruses. Because EBV 
preferentially infects B lymphocytes, the virus is classified under the genus 
lymphocryptovirus (Kieff and Rickinson, 2001). 
An Epstein-Barr virion is a spherical particle of about 110 nm in diameter. Its surface is 
formed by an envelope derived from the host cell nuclear or plasma membrane and studded 
with viral glycoproteins (Yamaguchi et al., 1967). From the envelope inwards is a protein 
tegument followed by an icosahedral nucleocapsid. The 162 capsomeres of the nucleocapsid 
enclose the viral genome that is wrapped around a toroid-shaped protein core.  
The EBV genome is a linear double stranded DNA of 184 kb that consists of repeats and 
unique sequences (Baer et al., 1984). Variable numbers of reiterated, 0.5 kb direct repeats 
called terminal repeats (TR) are located at both ends of the genome. The number of these 
repeats can vary among EBV strains and progenies of EBV replication. In latently infected 
cells, the number of TR in the viral genome usually remains constant. Analysis of TR, 
therefore, is conducted to determine whether a group of latently infected cells arose from a 
single progenitor. Between the TR, two largely unique sequences that contain almost all of the 
genome coding capacity are separated by a stretch of a variable number of 3 kb repeats (called 
internal repeats). The unique sequences also include perfect and imperfect tandem repeats of 
variable lengths, mostly within the nearly hundred open reading frames (ORFs) identified in 
the EBV genome (Kieff and Rickinson, 2001). 
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The EBV genome was sequenced from a BamHI fragment library. Consequently, EBV 
genetic elements like genes and promoters are referenced to the corresponding BamHI 
fragment. Thus, the EBV major envelope glycoprotein gp350 is also referred to as BLLF1, for 
BamHI L fragment, leftward ORF number 1. Such nomenclatures are still widely used. Well 
characterized gene products are more popular with alternative names. For example, the EBV 
proteins expressed during viral latency are called Epstein-Barr nuclear antigens (EBNAs) or 
latent membrane proteins (LMP). 
 
1.1.2 Epidemiology and clinical manifestations 
Two types of EBV are found in humans (Zimber et al., 1986). Type 1, previously called type 
A, is far more common in most populations. Type 2 (previously type B) is nearly as common 
as type 1 in equatorial Africa and Papua New Guinea, and is frequently encountered in human 
immunodeficiency virus (HIV) infected individuals.   
The two types differ mainly in the genes that code for EBNA2, EBNA-leading protein 
(EBNA-LP; also known as EBNA5) and the three proteins of the EBNA3 family (EBNA3A, -
3B and -3C; alternatively known as EBNA3, -4 and -6, respectively). Individual isolates of 
type 1 or type 2 EBV from widely different geographic areas can also differ by single base 
changes and repeat reiteration frequency. Persistent infection with more than one EBV type or 
strain is not unusual, particularly for more promiscuous and immunocompromised people.  
Two distinct epidemiological patterns of EBV infection can be observed in different 
populations. These appear to be closely related with the socioeconomic status (Crawford, 
2001). In developed countries, two peaks of infection are seen: the first in very young pre-
school children up to six years of age, the second in young adults 14 to 20 years of age. 
Eventually, up to 95% of all adults worldwide are infected. In developing and underdeveloped 
societies, infection occurs at a much earlier age. Serological surveys for immunoglobulin G 
(IgG) antibodies against the viral capsid antigen (VCA) have shown that in the developing 
world most children become infected with the virus by three years of age. Almost 100% 
become EBV-seropositive within the first decade of life (Evans and Niederman, 1989). 
Primary infection with EBV during early childhood is mostly non-clinical with minor 
common cold like symptoms. Rare cases of primary infection in early childhood and about 
half of those with delayed primary infection, however, manifest with the clinical syndrome of 
infectious mononucleosis (IM) (Papesch and Watkins, 2001; Khanna et al., 1995). IM is an 
acute febrile illness characterized clinically by pharyngitis, lymphadenopathy, splenomegaly, 
and hematologically by lymphocytosis with more than 10% atypical mononuclear 
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lymphocytes. Serologically, IM is characterized by elevated heterophile antibody titers and 
the development of anti-EBV antibodies (Niederman et al., 1968). EBV achieves its broad 
distribution in the population through multiple modes of transmission of which parent-to-
child salivary transmission appears to be the major route. The practice of chewed feeding and 
thus early salivary contact within families is generally thought to be the cause of very early 
exposure to the virus in the developing world. In the Western world, the second peak of 
infection is perhaps a reflection of the salivary exchange during early adolescence. Hence, 
acute EBV infection is popularly known as “kissing disease”. 
Besides salivary transmission, EBV can potentially be transmitted through other routes. In 
seropositive individuals the virus has been reported to be able to replicate in cervical epithelia, 
implicating that EBV may be transmitted sexually (Naher et al., 1992; Portnoy et al., 1984). 
Further, pregnant woman shed virus in their milk, prompting the hypothesis that mammary 
transmission also contributes to the early life acquisition of virus by babies and toddlers. EBV 
can also replicate in peripheral blood cells and thus can also be transmitted through 
transfusions and transplantations (Alfieri et al., 1996; Cen et al., 1991). 
 
Table 1. EBV-associated diseases of lymphoid origin (adapted from Williams and Crawford, 2005).  
 
Besides IM, EBV is associated with an increasing list of illnesses (Kawa 2000; Young and 
Rickinson, 2004). Many of these EBV-associated diseases are malignancies, and EBV has 
been implicated in the etiology of at least some of these tumors. Since EBV is a ubiquitous 
virus, however, causal associations are difficult to demonstrate. Some diseases of lymphoid 
origin associated with EBV are listed in Table 1. 
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1.1.3 Latent and lytic infection 
EBV preferentially infects B cells. This tropism is at least partly a reflection of the high level 
expression of CD21, the principal receptor for EBV, on B cells. CD21 on B cells serves as 
cellular receptor for the viral ligand, the glycoprotein gp350 (Fingeroth et al., 1984; Tanner et 
al., 1987). Gp350-deficient EBV poorly infects B cells although some infection seems to 
occur (Janz et al., 2000).  
Two distinct types of EBV infections can be detected in cells that the virus can infect: (i) lytic 
replication of the virus which leads to production and eventually release of infectious viral 
particles, and (ii) latent infection of cells in which the viral genome circularizes upon entry 
into the nucleus, maintains itself usually as an episome, and is propagated to progeny of the 
infected cell (Adams and Lindahl, 1975; Hurley and Thorley-Lawson, 1988). Infection of 
primary B cells with EBV in vitro causes growth-transformation of the infected cells and the 
outgrowth of lymphoblastoid cell lines (LCLs). Under favorable conditions, virus in latently 
infected cells can reactivate and enter the lytic cycle (Bornkamm and Hammerschmidt, 2001) 
which involves lytic viral promoter activity and expression of lytic cycle genes (almost all of 
the genes encoded by the viral genome). Depending upon the chronology of their transcription 
during lytic replication, EBV genes are identified as immediate early, early and late genes 
(Rickinson and Kieff, 2001). The viral transactivators BZLF1 and BRLF1 are the only 
currently known immediate early genes. Their products initiate lytic replication (Chevallier-
Greco et al., 1986). At least thirty EBV genes are grouped as early genes and another thirty as 
late genes. The products of early genes act as transactivators for the expression of other genes 
or are involved in viral DNA replication. Late genes are expressed temporally later but are 
formally categorized as late based on the marked reduction in their mRNA abundance in the 
presence of viral DNA replication inhibitors. In general, late genes are those that code for 
structural components including viral glycoproteins.  
As opposed to lytic replication, a maximum of nine gene products, known as EBV latency 
proteins or antigens, can be detected during latency along with two untranslated RNAs (called 
EBERs for Epstein-Barr encoded RNAs) (Kieff and Rickinson, 2001). The latency antigens of 
EBV include six nuclear proteins, designated EBNA1, -2, -3A, -3B, -3C, and –LP, as well as 
three integral membrane proteins, namely the latent membrane proteins LMP1, -2A and -2B.  
Among different latently-infected cells the spectrum of latency proteins expressed can differ. 
Depending on the expression profile, latently-infected cells are said to be in different types of 
latency (Kuppers, 2003). Originally three types of latency programmes were described. 
However, recent studies have proposed the possibility of additional patterns of gene 
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expression during latency. The viral products detectable in the different forms of latency and 
their occurrence are shown in Table 2. 
 
Table 2. EBV gene latency programmes (adapted from Küppers, 2003). 
 
1.1.4 EBV infection in the natural host 
In the most common mode of transmission, viral entry into the oropharynx of a naïve host is 
followed by the appearance of symptoms after an incubation period of four to six weeks. By 
that time, cell free virus can be obtained from throat washings (Sixbey et al., 1984). In which 
cells of the oropharynx EBV replicates after primary infection is still debated. The absence of 
detectable EBV DNA in the throat and peripheral blood of patients with X-linked 
agammaglobulinemia that lack B cells provides circumstantial evidence to the argument that 
B cells infiltrating the oral epithelium are the sites of primary virus replication (Faulkner et 
al., 1999). 
Besides the shedding of infectious virus in salivary secretions, primary infection is also 
marked by a generalized infection of the circulating B cell pool in which virus colonization in 
progress can in fact be witnessed before the onset of symptoms. During acute disease 0.1 to 
1% (in exceptional cases up to 10%) of circulating B cells stain positive for EBNAs or 
EBERs, which are reliable markers of EBV latent infection (Tierney et al., 1994). The 
inability to detect virus in freeze-thaw extracts of these cells suggests that these B cells are in 
fact latently infected in vivo, although some lytic cycle gene transcription activity can be 
detected in freshly isolated B cells from IM patients (Prang et al., 1997). Also, transcription 
profiling of freshly isolated B cells from IM patients shows mRNA expression characteristic 
of latency III, suggesting that these B cells are growth-transformed (Laytragoon-Lewin et al., 
1997). Promoter activity studies in the circulating B cell pool of IM patients have, however, 
also detected cells with other forms of latency. EBER-positive B cells in IM patients have 
been found to range from large blast like cells similar to the Reed Sternberg cells in Hodgkin's 
lymphoma (similar also in the viral gene expression pattern: negative for EBNA2 and positive 
for LMP1) to small cells that are negative for EBNA2 and LMP1. Medium sized 
lymphoblastoid cells with a LCL-like latency III expression profile are also among the EBER-
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positive cells along with intermediates that express EBNA2 and no LMP1 (Niedobitek et al., 
1997; Kurth et al., 2000). These are thought to be recently infected cells that are progressing 
to the LMP1 positive state. It is unclear how these different forms of infection interrelate in 
time but from analysis of the immunoglobulin (Ig) gene loci of B cells it has been shown that 
different cell phenotypes can be generated within the same EBV-infected B cell clone (Kurth 
et al., 2000). Ig gene loci analyses have also demonstrated that the B cell clones expanding 
after EBV infection carry preferentially, if not exclusively, somatically mutated Ig genes, 
indicating that they are memory B cells (Kurth et al., 2000). This preferential expansion or 
survival of infected memory as opposed to infected naïve B cells is yet to be understood. 
With subsidence of the symptoms of IM, virus replication in the oropharynx decreases. 
However, healthy virus carriers, including those that did not develop IM, continue to shed low 
levels of the virus from the oropharynx (Ling et al., 2003). Replication of virus in other 
mucosal sites has been reported, suggesting that once the virus has maintained a latent 
infection, reactivation can occur at any mucosal site with a B cell infiltrate (Sixbey et al., 
1986; Egan et al., 1995). Terminal differentiation of infected B cells into plasma cells has 
been shown to trigger the initiation of lytic replication of EBV in vivo (Laichalk et al., 2005). 
EBV-infected B cells can be detected in the peripheral blood as well as lymphoid tissues of 
healthy carriers throughout life. The frequencies are much lower than in acute IM. Based on 
polymerase chain reaction (PCR) of viral genes on limiting numbers of cells, the frequency of 
EBV-infected B cells in the peripheral blood has been determined to range from 1 in 104 to 1 
in 106 B cells (Babcock et al., 1998). EBV-positive B cells in healthy carriers differ 
phenotypically from those in IM in that the former are not activated lymphoblasts. EBV-
positive B cells in healthy carriers are resting IgD-and IgM-negative memory B cells 
(Babcock et al., 1998). The sequestration of EBV in the memory B cell compartment in 
healthy carriers is in accordance with the observation that predominantly B cells with a 
memory Ig genotype expand during primary infection. 
The EBV gene expression profile of B cells in healthy carriers is also different from that seen 
in IM. The narrowing of the viral gene expression profile from primary infection to the carrier 
state is consistent with the reversion of the infected B cell from an activated to a resting 
memory phenotype. In the carrier state, viral antigen expression is often abrogated and viral 
transcription is limited to the non-coding EBERs (Miyashita et al., 1995). This type of latency 
is designated latency 0.  
EBV-positive B cells in the lymphoid tissues of healthy virus carriers are found at frequencies 
similar to those in peripheral blood. However, the types of latency observed in lymphoid 
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tissue B cells are more heterogeneous than those detected in peripheral blood B cells 
(Rickinson and Kieff, 2001).  
 
1.1.5 EBV infection in vitro 
B lymphocytes derived from peripheral blood, tonsils or fetal cord are readily infected with 
EBV in vitro. Earlier stage B cells like those from the bone marrow or from fetal blood are 
also permissive for infection but the infection efficiency is about ten percent of that of 
peripheral blood B cells. The same applies for leukemic B cells and EBV-negative BL cells 
(Tatsumi et al., 1986; Calender et al., 1987; Doyle et al., 1993; Avila-Carino et al., 1994). 
EBV can also infect T cells, NK cells, some epithelial cell lines, and some carcinoma cell 
lines in vitro with even lower efficiencies (Kanegane et al., 1996; Yoshiyama et al., 1997; 
Imai et al., 1998).  
About 10% of primary B cells infected with EBV in vitro become latently infected and give 
rise to a growth-transformed LCL (Nilsson et al., 1971). LCL typically expresses all nine 
latency proteins of EBV. Thus, unlike latently infected B cells in the healthy virus carriers 
where the viral genome is nearly silent, the viral genome in LCL is not inactive. It is latent 
only in the sense that lytic replication rarely occurs.  
The viral latency gene products maintain the latent infection and induce continuous 
proliferation of the previously resting B cell. B cells growth-transformed by EBV are similar 
to B cells stimulated by antigen, mitogen, or interleukin-4 (IL-4) and CD40 ligation, express 
similar cell surface markers and adhesion molecules, secrete Ig, and grow in clumps (Vyth-
Dreese et al., 1995). EBV-immortalized B cells may continue to secrete Ig even after years in 
culture and some of them undergo class switching in vitro when exposed to IL-4 (Steel et al., 
1974; Litwin et al., 1974). 
Wild-type EBV for in vitro use can be obtained from virus carriers (who intermittently shed 
EBV in the saliva) and from EBV-positive cell lines in culture. Although the outcome of in 
vitro infection of primary B cells is the conversion of infected cells to continuously 
proliferating LCLs which are in general non-permissive for lytic replication, few cells in LCL 
cultures may spontaneously become permissive for lytic replication. The rate of spontaneous 
lysis in cell lines known to be good virus producers is around 1% (Kieff and Rickinson, 
2001). The phenomenon of few cells going into spontaneous lysis also holds true for EBV-
positive BL cells (Kieff and Rickinson, 2001). Cell lines derived from EBV-positive BL are 
often more permissive for lytic replication than LCL. However, EBV-positive BL cell lines 
established from EBV-negative BL tumors by infection with EBV in vitro are less permissive 
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than LCLs (Kieff and Rickinson, 2001). The marmoset B cell line B95.8 infected with wild-
type EBV is commonly used as a source of virus for in vitro studies (Miller et al., 1974).  
Lytic replication can be induced in permissive cell lines through a variety of means, for 
example exposure to chemicals (protein kinase C stimulators and DNA methylation inhibitors 
among others), starvation, and surface Ig crosslinking (Khanna et al., 1995). Expression of the 
viral lytic transactivator BZLF1 can also be used to induce lytic replication, although not all 
latently infected cells in which this protein is expressed enter the lytic cycle (Gradoville et al. 
1990). Lethal irradiation also induces lytic viral replication in latently infected cells. Virus 
production peaks four to five days after induction of lytic replication (Kieff and Rickinson, 
2001).  
 
1.2 Immune responses to EBV 
1.2.1 Humoral immune response 
Infection of the human host with EBV elicits antibody responses against a variety of viral 
antigenic determinants. Classically, the humoral response to EBV is divided into four distinct 
reactivities composed of multiple single antigens (Evans and Niederman, 1989). 
a) EBNA reactivity dominated by anti-EBNA1 antibodies, 
b) early antigen (EA) reactivity comprising responses against early lytic cycle proteins 
including BZLF1, the transactivator of lytic replication, 
c) viral capsid antigen (VCA) reactivity which includes responses to the nucleocapsid, and 
d) membrane antigen (MA) reactivity dominated largely by anti-gp350 responses and 
correlating with virus neutralizing activity. 
Information on primary antibody responses to EBV is derived largely from IM patients but 
appears to be similar in asymptomatic infections. At the time of development of the 
symptoms, IM patients have substantial titers of anti-VCA IgM antibodies and rising IgG 
titers to VCA and EA. Over the ensuing months the anti-VCA IgM response disappears. The 
anti-VCA IgG response falls to a stable steady level after an initial peak while the anti-EA 
IgG response falls faster and further than the anti-VCA IgG response to become either 
undetectable or to stabilize at very low levels. Anti-MA antibodies are usually of low titer 
during IM and anti-MA IgG titers rise relatively late in the disease but persist lifelong. A 
transient IgA response to gp350 is also detectable during IM (Sixbey and Yao, 1992). 
Of the nuclear antigens, an IgG response to EBNA2 (and probably to the EBNA3s) is 
detectable during IM whereas IgG responses to EBNA1 are usually not detectable until 
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convalescence (Henle et al., 1987). EBV LMP-specific antibody responses have not been 
detected in IM.  
The role of the humoral immune response in the control of EBV infection is unclear. The 
virus neutralizing antibody response could be involved in limiting spread of the virus. There 
have, however, also been reports that the anti-gp350 IgA antibodies may actually help virus 
spread to epithelial cells (Sixbey and Yao, 1992). The discrepancy in the time of development 
of anti-EBNA1 and -EBNA2 antibodies probably reflects the predominance of different types 
of latently infected cells at different times during and after IM (Rickinson and Kieff, 2001). 
Besides anti-EBV responses, the early phase of IM is also marked by elevated titers of serum 
IgM, IgG and IgA antibodies, probably as a result of the virus-driven polyclonal activation of 
the B cell system (Henle and Henle, 1979). Concomitant with this general increase is the 
transient appearance of a range of heterophile and autoantibodies, mostly of IgM class, which 
may also be products of virus-infected B cells (Garzelli et al., 1984). Of these various 
reactivities, heterophile antibodies with the capacity to agglutinate sheep and horse 
erythrocytes form the basis of the Paul-Bunnell-Davidsohn test that is diagnostic of EBV-
associated IM (Henle and Henle, 1979). 
Although healthy carriers are consistently positive for IgG antibodies against VCA, anti-
gp350 neutralizing antibodies and anti-EBNA1 antibodies titers can differ significantly 
between individuals. Many carriers also possess further reactivities like those to EA or to 
other EBNAs (Evans and Niederman, 1989). Again, the roles of these antibodies during 
persistent infection are not known, except that the virus neutralizing antibodies could 
contribute to overall control of the infection by preventing potential outbreaks of viremia. 
 
1.2.2 The CD8+ T cell response to EBV 
With the realization that humoral immune responses alone are not sufficient to control virus 
infection, the focus has shifted towards T cell-mediated responses to EBV. 
IM is marked by large numbers of atypical, mononuclear, predominantly CD8+ T 
lymphoblasts in the peripheral blood (Yata et al., 1973). The nature of the highly expanded 
CD8+ T cell response has long been debated. Findings of markedly skewed TCR Vβ subset 
distributions seen within CD8+ T cells of IM patients have been interpreted as bystander T 
cell activations or superantigen-induced expansions (Sutkowski et al., 1996).  
In healthy virus carriers CD8+ T cells specific for latent cycle antigens were detected and the 
epitopes were found to be predominantly derived from the EBNA3 family of proteins. 
Subsequently, similar studies were performed in patients with acute infection. In vitro 
Introduction 17
expanded CD8+ T cells from the peripheral blood of these patients also responded against 
latent antigens of EBV even at the height of primary infection (Steven et al., 1996). In 
addition, responses against allogeneic LCL were observed with these T cells, suggesting that 
additional specificities were present in these lines. Studies of the cytotoxic T lymphocyte 
(CTL) response in young infants within months of primary infection led to similar results 
(Tamaki et al., 1995). Precursor frequency analyses of T cells specific for a given latent cycle 
antigen using major histocompatibility complex (MHC) tetramers, however, demonstrated 
that these T cells accounted for only a small percentage of the total CD8+ T cell population in 
vivo (Callan et al., 1998). When lytic cycle antigens were included in such assays it became 
clear that multiple lytic cycle antigen specific T cells expand during IM, and that these are 
clearly more abundant than latent cycle antigen specificities (Callan et al., 1998). The most 
dominant lytic cycle antigens were identified to be derived from the immediate early proteins 
BZLF1 and BRLF1 and the early proteins BMLF1, BMRF1 and BALF2 (Bogedain et al., 
1995; Callan et al., 1998). Depending on the human leucocyte antigen (HLA) class I 
haplotypes, up to 50% of all CD8+ T cells in the peripheral blood of IM patients can be 
directed against a single epitope from a single lytic cycle antigen (Steven et al., 1997; Callan 
et al., 1998). These studies also revealed that the T cell reactivities against HLA-mismatched 
LCL reported in earlier studies are actually the result of cross-reactivity of certain EBV-
specific T cells against allo MHC-peptide complexes (Gaston et al., 1983; Burrows et al., 
1997). 
Similar, albeit less abundant, T cell reactivities were observed in healthy virus carriers. While 
CD8+ T cells with specificity for a single latent cycle antigen were shown to account for up to 
1% of the peripheral CD8+ T cell pool, T cells specific for a single lytic cycle antigen were 
found to be about five times more frequent (Tan et al., 1999). 
Most CD8+ T cells in patients with IM show an activated phenotype. During convalescence, 
most of these T cells die, most likely because antigen becomes limiting. As determined by 
MHC tetramer staining, both lytic and latent antigen specificities contract massively after IM, 
but with different kinetics (Silins et al., 1996). The remaining cells revert to a resting 
phenotype, although cells with memory or effector cell phenotypes have been detected. EBV-
specific T cell memory is best identified in regression assays (Moss et al., 1978). Unlike 
peripheral blood mononuclear cells (PBMCs) from EBV-seronegative donors, in vitro EBV-
infected PBMC from seropositive individuals fail to form LCLs unless T cells are depleted or 
inhibited. LCL-stimulated T cell memory against EBV is dominated by reactivities against the 
EBNA3 family of proteins followed by subdominant epitopes derived from LMP2 (Rickinson 
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and Moss, 1997). Responses to EBNA2, EBNA-LP, LMP1 and EBNA1 are rarely observed, 
and only weak responses to the BARF0 encoded polypeptides have been described. This 
marked hierarchy of immunodominance among latent cycle antigens is only partly 
understood. In the case of EBNA1, an internal glycine-alanine repeat prevents proteasomal 
degradation, and hence the generation of MHCI peptides (Levitskaya et al., 1995). 
Nevertheless, EBNA1-specific CD8+ T cells do exist at least in EBV-positive donors with 
certain MHC haplotypes, providing space for the argument that EBV-specific CD8+ 
responses might be primed by cells other than EBV-infected B cells (Munz, 2004). 
 
1.2.3 The CD4+ T cell response to EBV  
CD4+ T cells recognize peptide/MHCII complexes presented on the cell surface of 
professional antigen presenting cells, e.g. B cells, DCs, and macrophages. MHCII molecules 
are heterodimers that bind peptides of variable lengths (Engelhard et al., 1994). MHCII 
molecules are synthesized into the lumen of the endoplasmatic reticulum where they associate 
with the invariant chain. This chaperone prevents binding of peptides to MHCII molecules 
and escorts newly synthesized MHCII molecules into the endosomal/lysosomal compartment 
(Cresswell, 1996). Within this increasingly acidic vesicular system, invariant chain is 
degraded, allowing access of peptides to the peptide binding groove (Hsing and Rudensky, 
2005). These peptides are mostly derived from endocytosed proteins that are degraded in the 
lytic compartment. Exchange of CLIP, the cleavage product of invariant chain occupying the 
peptide binding groove, for peptides from endocytosed proteins is catalyzed by HLA-like 
molecules (Denzin et al., 2005). Vesicles with peptide-loaded MHCII molecules eventually 
traffic to the cell membrane where they can be recognized by CD4+ T cells. 
In contrast to MHCI molecules which present peptides derived mostly from intracellular 
proteins, MHCII molecules present peptides predominantly derived from extracellular and 
cell membrane proteins (Watts, 2004). This dichotomy of antigen presentation, however, is 
not as absolute as originally thought. Peptides derived from exogenous proteins can be 
presented on MHCI and this “cross-priming” appears to be essential for immune responses 
against viruses and tumors (Chen et al., 2004; Otahal et al., 2005). Likewise, endogenous 
presentation of antigens synthesized within the antigen presenting cell on MHCII has been 
implicated in the induction of tolerance and anti-viral immunity (Rudensky et al., 1991; 
Dongre et al., 2001). Recently, autophagy has been proposed as mechanism responsible for 
the endogenous presentation of cytosolic and nuclear antigens on MHCII (Nimmerjahn et al., 
2003; Paludan et al., 2005; Tewari et al., 2005; Zhou et al., 2005). Autophagy involves the 
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random sequestration of cytoplasm into membranous vesicles called autophagosomes which 
eventually fuse with endosomes/lysososomes thereby delivering their content into the MHCII 
processing and loading compartment (Yorimitsu and Klionsky, 2005) (Figure 1.1). Thus, T 
helper cells specific for an intracellular antigen may recognize target cells directly.  
 
Endosome 
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Lysosome
Autolysosome 
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engulfment 
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Figure 1. Peptides presented on MHCII molecules are derived from extracellular and intracellular 
proteins. 
Endocytosed antigens follow the classical pathway of MHCII presentation. Endosomes carrying the endocytosed 
antigens fuse with MHCII antigen presentation compartments (MIIC). Intracellular proteins enter the vesicular 
system during autophagy in which parts of the cytoplasm are spontaneously engulfed into membrane-bound 
organelles (autophagosomes) which subsequently fuse with lysosomes thereby delivering the proteins also to the 
MHCII antigen presentation pathway. 
 
CD4+ T cells are classically designated T helper cells because B cells specific for a given 
antigen cannot be activated to proliferate, form germinal centers, or differentiate into plasma 
cells, until they encounter a helper T cell that is specific for one of the peptides derived from 
the antigen (McHeyzer-Williams and McHeyzer-Williams, 2005). Subsequent studies 
revealed that T helper cells are the source of interferon-gamma (IFN-γ) required to activate 
macrophages to destroy intracellular microorganisms more efficiently (Pace et al., 1983). 
More recent studies identified an important function of T helper cells in licensing DCs to 
prime CD8+ T cells (Smith et al., 2004). Thus, T helper cells play a central role in the 
orchestration of humoral and cellular immune responses. Following endogenous presentation 
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of intracellular antigens on MHCII, T helper cells may also exert direct effector functions on 
target cells.  
The multiple effector functions of CD4+ T cells appear to correlate with the pattern of 
cytokines secreted upon activation. Accordingly, CD4+ T cells can be divided into several 
subtypes including T helper type (Th) 1 and 2 among others (Mosmann and Sad, 1996). 
Th1 cells are best identified by their secretion of IFN-γ upon target cell recognition. IFN-γ is 
able to activate macrophages and to inhibit proliferation of different cell types. In addition, 
IFN-γ enhances antigen presentation by inducing expression of MHC molecules (Christensen 
et al., 1999; Robertson et al., 2001; Paludan et al., 2002).  
Th2 type CD4+ T cells are the classical T helper cells. They produce IL-4 and IL-13, but little 
or no IFN-γ, and help naïve B cells to proliferate and secrete Ig (Parker, 1993). 
The term Th3 has been used to describe unique cells that produce mainly transforming growth 
factor-ß (TGF-ß) in response to antigen. Because of the T cell inhibitory function of TGF-ß, 
these T cells are also called regulatory T cells or TR1 cells and appear to play an important 
role in preventing responses to food antigens (Faria and Weiner, 2005). More recently, a 
different type of regulatory T cells, characterized by the expression of CD4 and CD25 has 
been identified (Sakaguchi, 2004). These regulatory T cells are able to suppress T cells 
responses by an IL-10- and TGF-β−independent, but cell contact-dependent mechanism(s). 
These T cells seem to play an important role in preventing autoimmune responses (Lan et al., 
2005). In addition, these regulatory T cells have been shown to prevent or ameliorate other 
immunopathologic syndromes such as graft-versus-host disease and graft rejection. There is 
even evidence that normal immune responses can be inhibited by these T cells, so they may 
have a role in controlling the extent, duration, and perhaps even the quality of normal as well 
as pathologic immune responses (O`Garra and Vieira, 2004). A recent report on regulatory T 
cells specifically recognizing epitopes derived from the EBV nuclear antigen EBNA1 
suggested that such regulatory T cells may play a role in virus persistence (Voo et al., 2005).  
Knowledge on the CD4+ T cell response to EBV is still scarce. In patients with IM, CD4+ T 
cells do not expand to the same degree as CD8+ T cells, and only few EBV-specific CD4+T 
cells have been described. Information on the CD4+ T cell memory to EBV in the healthy 
carrier is also still rudimentary despite recent suggestions that CD4+ T cells can recognize 
EBV-infected cells directly, and, more importantly, that they are pivotal in the maintenance of 
long term cellular immunity (Callan, 2004). The first CD4+ T cells reactive against EBV were 
identified as rare clones in LCL-stimulated CTL preparations (Rickinson and Moss, 1997). In 
recent years, the CD4+ memory to latency antigens has been analyzed more systematically 
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(Munz et al., 2000; Mautner et al., 2004; Long et al., 2005). Some reports suggest a hierarchy 
of immunodominance among the latent cycle antigens with EBNA1 and EBNA3C being the 
dominant ones (Leen et al., 2001). Further studies are needed to verify this. The recognition of 
endogenous EBNA1 on EBV-infected cells by CD4+ T cells is also controversially discussed. 
(Munz et al., 2000; Mautner et al., 2004). Thus, important issues regarding the CD4+ T cell 
response to EBV are still unresolved. 
 
1.3 EBV in the immunocompromised 
Immune impairment is typically associated with reduced EBV-specific CTL responses, 
increased virus shedding, increased viral genomic load, increased numbers of infected B cells 
in the blood, and also altered anti-EBV antibody profiles. These phenomena have been 
observed partly or wholly in long term low level immunosuppressed, solid organ transplant 
(SOT) recipients and also in HIV-infected individuals (Riddler et al., 1994; Baldanti et al., 
2000).  
As noticed first in bone marrow and cardiac transplant recipients, and later also in HIV-
infected individuals, immunocompromised patients also differ from immunocompetent 
individuals in the number of viral strains they carry (Yao et al., 1996a). While simultaneous 
infection with multiple viral types and strains is rarely seen in immune competent hosts, HIV-
infected individuals with detectable T cell impairment are frequently co-infected with type 1 
and type 2 EBV strains (Yao et al., 1996b). 
The effects of immune impairment are often most pronounced in bone marrow transplant 
(BMT) recipients in whom T cell function is more strongly suppressed, and in seronegative 
transplant recipients who often acquire their primary infection iatrogenically through the 
transplant or through transfusions. In BMT recipients, EBV DNA load in PBMC can reach 
very high levels in the first three to six months after transplantation which correlates with the 
risk of developing B cell post transplant lymphoproliferative disease (PTLD) (Gottschalk et 
al., 2005). 
The link between sustained immunosuppression of transplant recipients and increased 
incidence of lymphoma, especially PTLD, has long been apparent and the association with 
EBV is now widely recognized. One major risk factor for PTLD development is the intensity 
of T cell suppression. Thus, patients receiving renal and liver transplants have overall 
incidence rates of 1% to 2%, versus 3% to 8% for lung and heart transplantations where 
higher levels of immunosuppression are necessary (Gottschalk et al., 2005). In BMT settings, 
the overall incidence rates are less than 1%. However, T cell depletion of the marrow graft 
can increase incidence rates to 12% to 24% (Nalesnik, 1998). Because in most BMT protocols 
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host lymphoid cells are totally ablated, PTLDs usually arise from infected donor B cells. 
Consequently, it is now a standard practice to treat high EBV load following stem cell 
transplantation with the monoclonal anti-CD20 antibody Rituximab which rapidly lowers the 
viral load by eliminating circulating B cells and has been shown to reduce the incidence of 
PTLD (van Esser et al., 2002). 
The patient's EBV status at the time of transplantation is also an important risk factor for 
PTLD. A survey of SOT recipients showed a 20-fold increased incidence in seronegative 
recipients, explaining why younger children are at increased risks (Ho et al., 1985). The viral 
genomic load in transplant recipients has also been used to assess risk and in deciding 
prospective patients for adoptive T cell therapy (van Esser et al., 2001). The limited success 
of acyclovir in the prevention of PTLD has raised the question to what extent ongoing virus 
replication might increase the risk for PTLD development. 
Classic PTLDs mostly arise within the first two years of transplantation. At least 90% of such 
lesions are EBV-associated and are either oligoclonal or monoclonal based on EBV TR and Ig 
gene analysis (Chadburn et al., 1997). By immunostaining, most EBV-associated PTLD 
lesions are dominated by EBNA1-, EBNA2-, and LMP1-positive cells. A minority of these 
tumor cells are EBNA1-positive with low or undetectable EBNA2 and LMP1. A small 
proportion of PTLDs have acquired mutations in the p53 and c-myc gene loci. PTLDs 
showing complex chromosomal aberrations often display more restricted forms of latency 
(Locker and Nalesnik, 1989; Knowles et al., 1995).  
Many PTLDs were observed to regress when immunosuppressive therapy was reduced 
probably due to a re-emergence of the patient’s anti-EBV T cell response (Khatri et al., 1999). 
Therefore, a reduction in immunosuppression is the first treatment option for PTLD. 
Similar to transplant recipients, HIV-infected individuals are at increased risks of EBV-
associated B cell lymphoma development. The spectrum of tumor types in HIV positives is 
more diverse than that seen in the transplant setting (Gaidano et al., 1998). At least one major 
category of EBV-associated B cell lymphoma is essentially analogous to PTLD lesions and 
appears in end-stage AIDS when patients are profoundly immunocompromised. Most of the 
AIDS lymphomas presenting in the central nervous system are of this type.  
 
1.4 Immunological approaches to control EBV infection 
The identification of the major envelope glycoprotein gp350 as the dominant target of the 
virus neutralizing antibody response in the 1980s fuelled attempts to develop a prophylactic 
EBV vaccine (Epstein 1986; Morgan and Wilson, 1997). It is now clear that neutralizing 
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antibodies alone or in combination with cell-mediated responses to a single envelope 
component are not likely to offer long lasting sterile immunity, although such an approach 
could be expected to sufficiently reduce the free viral load which might be sufficient to 
prevent primary infections from leading to IM or, in immunocompromised patients, to PTLD.  
The recognition of the importance of CD8+ T cells in the control of primary infection have 
opened up possibilities of inducing CD8+ responses by priming naïve individuals through the 
use of synthetic peptides or polyepitope vaccine constructs (Moss et al., 1996). Novel 
therapeutic approaches to tackling EBV-associated tumors are constantly tested. Considerable 
progress has been made in the treatment of EBV-associated lymphoproliferative disorders 
(Gottschalk et al., 2005). 
 
1.4.1 T cell therapy of EBV-associated lymphomas 
In the SCID mouse model, EBV-positive human B cell lymphomas can be induced by 
reconstituting the mouse with PBMC from EBV-seropositive individuals and can be cured or 
growth impaired by the infusion of T cells from the autologous donor (Donjon et al., 1983). 
An analogous strategy in BMT recipients showed that the transfusion of small numbers of 
PBMC from the healthy seropositive donor can reverse PTLD growth. Although this regimen 
led to dramatic increases in the EBV-specific T cell frequencies, the incidence of graft-versus-
host disease also went high. Subsequent studies demonstrated that LCL-stimulated PBMC 
could mediate equally effective tumor control without causing graft-versus-host disease 
(Rooney et al., 1995; Heslop and Rooney, 1997). This approach could also be used to reduce 
high EBV genome loads in the blood of patients at risk. In the SCID mouse model infused T 
cells were found to home preferentially to tumor sites (Lacerda et al., 1996). This together 
with the finding that non-specific CTLs fail to reduce viral load implied that EBV-specific T 
cells are indeed the effector cell population that serve the clinical purpose. This was further 
underlined by the observation that a tumor growing in face of T cell therapy had lost EBV 
epitopes against which the infused T cell populations were predominantly directed 
(Gottschalk et al., 2001). PTLD in SOT recipients are usually derived from host B cells rather 
than donor cells and thus pose a logistic problem. Although active T cell populations can still 
be generated from post transplantation bleedings when the patient is already 
immunosuppressed, alternative strategies like using allogeneic or partially MHC-matched 
donor-derived T cell populations are being explored (Haque et al., 2001). Such latter T cell 
populations would not be expected to stay long-term but could provide the immediate rescue, 
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at least in patients who underwent primary infection during transplantation, and thus have not 
developed anti-EBV T cell immunity yet. 
Most EBV-associated malignancies other than PTLD show more restricted patterns of latent 
antigen expression and, therefore, are believed to be difficult to target through CTL therapy 
(Rickinson and Kieff, 2001). Recent studies, however, have shown that an EBV-specific T 
cell population can be generated by stimulating PBMC from patients with Hodgkin's disease 
with autologous LCL, that these T cells persist for several months after infusion and that they 
cause a reduction in the EBV genomic load (Bollard et al., 2004a).  
CD8+ T cells recognizing latent antigens are thought to be the major effectors against PTLD. 
However it is usually acknowledged that CD4+ T cells are important in facilitating CD8+ T 
cell expansion and survival or as effectors in their own right (Kalams et al., 1998; Hung et al., 
1998). 
Due to the often rapid progression of PTLD, T cell lines for therapy have to be prepared 
prophylactically for patients at risk. This precludes a broader clinical application of this labor 
and cost-intensive adoptive T cell therapy. The development of alternative protocols that 
permit the generation of EBV-specific T cell lines more rapidly even after tumor 
manifestation is dependent on the knowledge of viral antigens and epitopes.  
 
1.5 Aim of the work 
The aim of this work was to characterize the EBV-specific CD4+ T cell response in EBV-
negative (cord blood donors and EBV-negative adults) and EBV-positive individuals (during 
the acute and persistent phase of infection) and to identify the immunodominant antigens. The 
characterization of the immunodominant MHCII restricted EBV antigens should not only 
provide insight into how protective immunity is established but should also help in the 
identification of immunotherapeutic strategies for tumors with a more restricted viral 
expression profile than PTLD. Taken together the findings of this work were expected to 
contribute to a better understanding of the host-pathogen interaction as well as to novel 
therapeutic approaches against aggressive EBV-associated diseases. 
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2. Materials and Methods 
 
This chapter describes the materials and methods used in this work. Where materials were 
bought from commercial manufactures, the manufacturer is indicated in parentheses after the 
material name where it appears first. For materials obtained as gifts the source is similarly 
indicated in parentheses. Where the source of commercial material has not been indicated 
they were bought from one of the following: Amersham, Becton Dickinson, BioRad, 
Calbiochem, Corning, Dianova, Eppendorf, Greiner, Integra, Invitrogen, MBI-Fermentas, 
Merck, Millipore, NEB, Neolab, Nunc, PAA, Packard Instruments, Perkin Elmer, Promega, 
Qiagen, Roche/Boehringer, Sartorius, Sigma-Aldrich, Stratagene.  
 
2.1 Laboratory equipments 
Cell culture CO2 incubators (Heraeus; ThermoForma) 
Centrifuges (Eppendorf; Sorvall; Beckman; Hettich) 
-80°C freezers (Colora) 
-20°C freezers (Liebherr) 
4°C refrigerators (Liebherr) 
Bacteria-incubator (Haereus) 
Bacteria shaker (New Brunswick Scientific) 
Cell counting chamber (GLW) 
Elektroporation equipment Gene Pulser II (BioRad) 
ELISA-Reader (Tecan) 
FACS-Scan equipment (Becton-Dickinson) 
Gel electrophoresis chamber (Invitrogen) 
Light-optical microscope (Carl Zeiss) 
Milli-Q water preparation equipment (Millipore) 
pH-Meter (Knick) 
Pipettes (20, 200, 1000 μl) (Gilson) 
Pipette Boy (Integra) 
Power supply Power-Pac 300 (BioRad) 
Spectrophotometer (Eppendorf) 
Sterile bench (Bio Flow Technik) 
UV-Transilluminator (UVP Inc.) 
Vortex Genie 2 (Bender & Hobein) 
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2.2 Cell biology materials and methods 
2.2.1 Eukaryotic cell culture materials 
The recipes used for the preparation of different cell culture media and solutions are as 
follows: 
T cell media (for culture of T cells) 
500 ml AIM-V (Invitrogen)  
10% heat-inactivated pooled human serum (preparation described below) 
2 mM L-glutamine (PAA) 
10 mM HEPES (Invitrogen) 
50 µg/ml gentamicin (Invitrogen) 
 
LCL media 
500 ml RPMI 1640 (PAA)  
10% fetal calf serum (FCS) (Biochrom) 
1% non-essential amino acids (Invitrogen)  
1 mM sodium pyruvate (Invitrogen) 
2 mM L-glutamine (PAA) 
50 µg/ml gentamicin (Invitrogen) 
 
Insect cell media 
500 ml Grace’s insect media (Invitrogen) 
10% FCS  
1% fungizone ((Invitrogen) 
50 µg/ml gentamicin 
 
Supplemented DMEM media 
500 ml DMEM (PAA) 
10% FCS 
50 µg/ml gentamicin 
2 mM L- glutamine 
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PBS 
2 g potassium chloride (KCl), 2 g potassium dihydrogen phosphate (KH2PO4), 80 g sodium 
chloride (NaCl) and 14.3 g disodium hydrogenphosphate (Na2HPO4:2H2O) dissolved to a 
final volume of 10 l in deionized sterile water, pH adjusted to 7.2 to 7.4, sterile filtered.  
 
Disposable cell culture material 
140 mm and 100 mm cell culture plates (Nunc) 
6-well, 12-well, 24-well, 48-well, 96-well flat bottom plates (Becton Dickinson) 
96-well round bottom plates (Corning) 
96-well V bottom plates (Nunc) 
cotton-stuffed plastic pipettes (2 ml, 5 ml, 10 ml, and 25 ml) (Corning) 
1 ml, 200 µl, 20 µl and 10 µl stuffed pipette tips (Molecular Bioproducts) 
10 ml, 200 ml and 400 ml cell culture flasks (Greiner) 
15 ml and 50 ml Falcon tubes (Becton Dickinson) 
1.5 ml and 2 ml Eppendorf tubes (Eppendorf) 
500 µl PCR tubes (Sarstedt) 
 
2.2.2 General conditions for eukaryotic cell culture 
All cells were incubated in a cell culture incubator with 5% CO2 at 37°C except for insect 
cells (described separately below). All media for cell culture were stored at 4°C for no longer 
than three months, and were used within two weeks following addition of serum. Serum was 
stored at -20°C for no longer than six months. Other supplements were kept at temperatures 
recommended by the manufacturer. Cell manipulations were performed in a biological 
containment cabinet (hood) under strict aseptic techniques using disposable plastic pipettes or 
autoclaved glass pipettes with cotton plugs. Cells in culture were refed with fresh growth 
medium as necessary, depending upon the growth and media consumption. Cells were 
ordinarily expanded and frozen to maintain a frozen inventory. Freezing of cells was done in 
1.8 ml cryotubes (Nunc) with 5 X 106 to 1 X 107 cells in 1.8 ml of freezing media consisting 
of 10% dimethylsulfoxide (DMSO, Merck) in fetal calf serum (FCS). For allowing slow 
freezing, tubes with cells to be frozen were put in propanol compartments (Nunc) in -80°C 
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freezers. Within a week the tubes were transferred to liquid nitrogen tanks for long term 
storage.  
Frozen cells were allowed to thaw rapidly at 37°C and transferred into a 15 ml Falcon tube in 
which they were washed in RPMI 1640 twice by centrifuging the cells at 1000 X g for 5 min 
in between washes. The cells obtained thereafter were maintained in fresh warm media. 
(Unless otherwise stated all centrifugation steps described below used to pellet cells were 
performed at 1000 X g for 5 min at room temperature). Thawed cells were treated for two 
weeks with mycoplasma removal agent (MP) to avoid mycoplasma contamination.  
EBV-negative BL cell lines, their EBV-positive convertants, and the marmoset B cell line 
B95.8 were maintained in suspension culture in cell culture flasks in LCL media.  
The adherently growing human fibroblast cell line Wi38 and the human embryonic kidney 
cell line 293T were cultivated in cell culture plates in supplemented DMEM media. They 
were split 1:4 every two to three days as necessary using 10 ml (or 5 ml) of 1 X Trypsin-
EDTA (PAA) to detach cells by incubation at 37°C for 5 min. The detached cells were then 
transferred to a 15 mlFalcon tube along with supplemented DMEM media, pelleted by 
centrifugation, resuspended in fresh supplemented DMEM media and brought out in new 
plates at desired cell densities.  
The insect cell line Sf9, also growing adherently, was maintained in a separate incubator at 
27°C in cell culture plates and cultivated in insect cell media. 
 
2.2.3 Separation of peripheral blood mononuclear cells from whole blood 
PBMC used in this work were obtained either from buffy coats or from freshly obtained 
peripheral blood. Peripheral blood was obtained from EBV-positive and -negative healthy 
donors, IM patients and cord blood donors. Peripheral blood of IM patients were obtained 
from the Children’s Hospital of the University of Technology, Munich. Cord blood samples 
were kindly provided by Dr. Andreas Moosmann (Clinical Cooperation Group “Molecular 
Oncology”, GSF). Studies on material of human origin were approved by the Ethical Board of 
the University of Technology, Munich. 
PBMC were isolated by density gradient purification. For this peripheral blood or buffy coats 
were collected in 50 ml Falcon tubes and treated with 0.5 mM EDTA to prevent coagulation. 
Samples were then diluted 1:1 in RPMI 1640, underlayed with 10 to12 ml Ficoll-Paque 
(Amersham) per 50 ml Falcon tube and centrifuged at 2000 X g without brakes for half an 
hour. This led to the collection of red blood cells at the bottom of the tube and white blood 
cells and platelets on top of the Ficoll phase. The white cell phase was carefully collected with 
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a pipette and transferred to a new Falcon tube diluted with RPMI 1640 and then centrifuged at 
1000 X g for 10 min. After the centrifugation, the supernatant was discarded and the cellular 
pellet washed twice in RPMI 1640. Cells pelleted by centrifugation were then resuspended in 
2 ml media, counted, and the cell suspension diluted with fresh media as required for 
subsequent applications.  
PBMC derived from buffy coats were used as feeder cells for the stimulation of T cell clones. 
Equal numbers of PBMC, derived from at least three different buffy coats, were mixed on ice 
for half an hour after which they were irradiated (40Gray), washed with RPMI 1640, and 
resuspended at 105 cells /µl. These were then used in T cell cloning media at 2.5 X 105/ml. 
 
2.2.4 Preparation of pooled human sera for T cell media 
For T cell media, sera prepared from voluntary donors were used. Whole blood obtained from 
peripheral veins was collected in 50 ml Falcon tubes and allowed to coagulate. The 
coagulated blood was centrifuged at 3000 X g for 15 min and the clot-free supernatant 
transferred to new tubes which were then centrifuged in the same conditions as before to get 
rid of any remaining cells. The clear serum was heat-inactivated at 56°C for half an hour. Sera 
obtained from multiple (at least three) donors were pooled and the pooled sera used for the 
preparation of T cell media. 
 
2.2.5 Establishment and culture of lymphoblastoid cell lines 
Several LCLs were established during this work. For this purpose PBMC obtained after 
density gradient centrifugation were resuspended at 1-2 X 106 cells per 100 µl in LCL media. 
100 µl of the cellular suspension were brought out per well of a 96-well flat bottom plate. 
Infection with EBV was performed by adding 100 µl of virus suspension in the presence of 
cyclosporine A at a final concentration of 0.5 mg/ml.  
Two types of LCLs were generated by using two different viral strains. The B95.8 wild type 
virus was obtained by filtration of cell-free supernatant of densely grown B95.8 cells through 
0.45 µl filters. The second EBV strain used was a laboratory derivative of the wild type virus. 
This laboratory strain called miniEBV differs from the wild type virus in that it is unable to 
undergo lytic replication. MiniEBV was kindly provided by Dr. Andreas Moosmann (Clinical 
Cooperation Group “Molecular Oncology”, GSF). After 24 hours half the medium was 
removed and replenished with cyclosporine-supplemented fresh LCL media. Infected PBMC 
were regularly inspected for media exhaustion and were replenished with cyclosporine-A-
supplemented LCL media as necessary. 104 cells/well of the human fibroblast cell line Wi38 
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were provided as feeders to cultures that failed to show B cell colonies within two weeks. 
Infected cells that started proliferating were transferred to 48-well and then subsequently to 
24-well plates. From there on, expanding cell lines were transferred to plastic flasks in which 
the B cell lines were maintained as long as used.  
EBV-immortalized cells were split regularly depending on proliferation. For this, the cells 
were resuspended by pipetting, half of the resuspension removed and replaced with fresh 
media. 
In this work wild type EBV-immortalized cell lines are called LCL and miniEBV-
immortalized cell lines are called miniLCL. 
LCLs were HLA class I and II typed at the Laboratory of Immunogenetics, LMU, Munich. 
 
2.2.6 Generation and maintenance of T cell lines and clones 
EBV-specific T cells lines were generated either by using autologous LCL or recombinantly 
expressed EBV protein-pulsed autologous PBMC as stimulators of peripheral blood T cells.  
LCL (or miniLCL)-specific T cell lines were generated by co-incubating 2 X 106 PBMC with 
2 X 106 γ-irradiated (80 Gy) LCL (or miniLCL) in one well of a 24-well plates in 2 ml T cell 
media. Within 48 hours, cultures were supplemented with 10U/ml recombinant human IL-2 
(Chiron). T cell lines were restimulated biweekly with irradiated LCL (or miniLCL) in the 
same fashion. 
For establishing EBV protein-specific T cell lines, 2 X 106 PBMC were incubated in 2 ml T 
cell medium typically with 500 ng/ml recombinant EBV protein in one well of a 24-well 
plate. (Expression, purification and quantification of recombinant proteins is described 
below). IL-2 was added to the cultures within 48 hours. For the restimulation of T cell lines, 2 
X 106 PBMC incubated with 500 ng/ml protein in one well of a 24-well plate for 24 hours 
were irradiated at 40 Gy and then co-cultured in 2ml T cell media in a well of a 24-well plate 
with 1 X 106 T cells from the last restimulation.  
Between restimulations, T cell lines were expanded depending on proliferation. Expansion of 
T cells was done by transferring half of a proliferating culture to a new well and then 
replenishing the wells with T cell media supplemented with 10 U/ml IL-2.  
In this work T cell lines have been qualified using the term passage (abbreviated p). This term 
followed by a number is used to identify the number of restimulations that the T cell line 
underwent. For example, a LCL-stimulated T cell line p10 indicates T cells obtained after 10 
restimulations with irradiated autologous LCL. 
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To obtain CD4+ T cell lines, unselected T cells were subjected to magnetic sorting. CD4+ T 
cell enrichment was achieved either by positive or negative selection. Magnetic sorting was 
also used for the enrichment of B cells by sorting CD19+ PBMCs or CD4-CD8- PBMCs. 
Since the steps are identical, the general method of magnetic sorting is described. 
Cells to be sorted were washed and resuspended at 107 cells in 80 µl MACS buffer (PBS with 
1% bovine serum albumin and 2 mM EDTA). The cells were then incubated on ice for 20 min 
with 20 µl Ig microbeads (Miltenyi). After the 20 min, the beads-labeled cells were washed 
once with MACS buffer, pelleted by centrifugation and then allowed to run through a MACS 
column (Miltenyi) on a magnetic stand equilibrated with 3 ml MACS buffer. The flow 
through, which contains unlabelled cells, was collected when cell depletions were performed. 
For collecting the positively selected cells, the column was removed from the magnetic stand 
and its content was siphoned out into a 15 ml Falcon tube with 5 ml MACS buffer. Either 
fraction was pelleted by centrifugation, washed in RPMI 1640 media, and resuspended in 
media for further use.  
T cell clones described in this study were derived from T cell lines by limiting dilution 
cloning. T cells at day 14 of the last restimulation were co-cultured with stimulator APC 
(prepared similarly as for the stimulation of the T cell lines) in cloning media consisting of T 
cell media supplemented with 10 U/ml IL-2, 250 ng/ml phytohemaglutinin (PHA) (Murex) 
and 2.5 X 105 /ml irradiated feeder cells consisting of PBMC of three donors at 0.3 to 3 T 
cells in 200 µl media/well in 96-well round bottom plates. After three days, most of the media 
was removed and replenished with IL-2-supplemented T cell media. After two weeks, 
outgrowing T cell clones were transferred to 48- or 24-well plates and restimulated in the 
same fashion. 
 
2.2.7 Preparation of dendritic cells from PBMC 
Myeloid DC were obtained by in vitro differentiation of precursors from peripheral blood. 
100 mm petri dishes were coated with 10 ng/ml human IgG in 10ml PBS for 10 min at room 
temperature. The plates were washed once with PBS and 5-7 X 107 PBMCs in 10 ml LCL 
medium brought out per plate. The cells were incubated for 30 min at 37ºC after which non-
adherent cells were removed by vigorous washing with PBS. The adherent remaining cells 
were exposed to 50 ng/ml GM-CSF (Berlex) and 100 ng/ml IL-4 (PAN) in 10 ml LCL media 
in order to induce DC differentiation. After two days at 37ºC, the cells were refed with fresh 
media supplemented with the same concentration of granulocyte-monocyte colony-
stimulating-factor (GM-CSF) and IL-4. These cells were either used within two days as 
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immature DC or were subjected to maturation with the same concentration of GM-CSF and 
IL-4 along with 10 ng/ml TNF-α (R&D) , 1 µg/ml PG-E2 (Sigma-Aldrich) and 10 ng/ml IL-
1β (R&D). After 24 hours of exposure to the maturation cocktail the cells were used as 
mature DC. 
 
2.2.8 Methods for T cells phenotype and function analysis 
2.2.8.1 Flow cytometric analysis of T cells  
T cells were analyzed by two-color flow cytometry for surface CD4, CD8, TCRαβ and 
TCRγδ expression. All fluorescence labeled antibodies were bought from BD Biosciences. 
For labeling the cells, approximately 3 X 105 cells were collected in a 1.5 ml Eppendorf tube, 
washed once with cold FACS buffer (PBS with 2% FCS) and incubated for 20 to 30 min on 
ice with an antibody against the surface molecule(s) in 100 μl FACS buffer. If the first 
antibody was not fluorescence-labeled, the cells were washed once with FACS buffer and 
then incubated for 20 min on ice with a fluorescence-labeled secondary antibody (specific for 
the first antibody) in a final volume of 100 µl FACS buffer. All incubations with fluorescence 
labeled antibodies were performed in the dark. After fluorescent labeling, cells were washed 
three times in 1 ml FACS buffer, pelleted and resuspended in 400 μl FACS buffer containing 
0.1 mM propidium iodide. Cell samples prepared in the aforementioned way were analyzed 
on a FACScan flow cytometer with CellQuest software (Becton Dickinson).  
 
2.2.8.2 Measuring T cell cytokine secretion by ELISA   
T cells were assayed for target cell recognition by measuring specific cytokine release using 
ELISA kits (R&D). T cells to be assayed were co-cultured with appropriate antigen 
presenting cells in 96-well plates in 200 µl of LCL media. Where indicated, antigen 
presenting cells had been preincubated with recombinant protein (for at least 24 hours) or 
peptide (for at least two hours) in 200 µl LCL media per well in 96-well plates. Following 
incubation, the target cells were washed extensively to remove excess protein or peptide, and 
co-cultured with 105 T cells. In control wells, APC alone and T cells alone were assayed. 
After 20 to 24 hours of incubation, the cell culture supernatant was harvested and the cytokine 
content measured following the general ELISA protocol provided by the manufacturer. Xread 
Plus software was employed for quantification.  
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2.2.8.3 IFN-γ and perforin ELISPOT assays 
IFN-γ ELISPOT assays were performed in 96-well nitrocellulose-lined microtiter plates 
(Millipore) principally following the protocols provided by the manufacturer. Briefly, plates 
were coated overnight at 4ºC with 100 µl of 10 µg/ml anti-IFN-γ mAb 1-D1K (Mabtech) in 
PBS. The following day, the plates were washed thrice with PBS and then blocked with T cell 
media at 37ºC for 1 h. After three washes with PBS, target and responder cells were added to 
the wells in a maximum total volume of 200 µl and the plate incubated at 37 ºC for 24 to 48 
hours. The cells were then removed by washing the wells thoroughly three times with PBST 
(PBS with 0.05% Tween 20) (Sigma–Aldrich). Next, 100 μl of 1 μg/ml biotinylated anti-IFN-
γ mAb 7-B6-1 biotin (Mabtech) in PBS were added per well and incubated for two hours at 
room temperature. Subsequently, the plates were washed six times with PBST and 100 µl of 
1:1000 diluted ExtraVidin peroxidase conjugate (Sigma–Aldrich) were added per well. After 
an hour of incubation at room temperature and another round of six washes, 100 μl of freshly-
prepared, 0.25 µm-filtered substrate solution were added per well. Depending on the 
development of color, the colorimetric reaction was terminated within 20 min by rinsing with 
tap water. The plates were air dried overnight and analyzed the next day under the light 
microscope for the number of spots in each well.  
Perforin ELISPOT assays were performed similarly with modifications as suggested by the 
manufacturers (Mabtech and Millipore). 
Substrate solution: 1 tablet each of Sigma FAST DAB and Sigma FAST Urea hydrogen peroxide (both from 
Sigma-Aldrich) in 10 ml deionised water.  
 
2.2.8.4 T cell cytotoxicity assay 
For measuring cytotoxicity of T cells, standard europium release assays were performed. 
Appropriate target cells were either left untreated or were labeled with 2 µM of peptides. 
After two hours of peptide labeling, target cells were washed thoroughly to remove excess 
peptide and labeled with BATDA reagent. 106 cells were labeled in 500 µl medium with 1 µl 
of BATDA reagent (8 mM, Perkin-Elmer) for 15 min at 37ºC. Labeled cells were run through 
a Ficoll gradient centrifugation step to remove dead cells and viable cells were washed, 
resuspended at 5000 cells/100 µl medium, and plated at 100 µl per well in 96-well V-bottom 
plates (Nunc). T cells were then added at different effector target ratios (10:1, 3:1 and 1:1). 
For measuring maximum and minimum release, 1% Triton X or medium only was added to 
the targets. All samples and controls were set in triplicates. The assay was incubated for three 
hours at 37°C after which 40 µl of the supernatant was carefully pipetted into 96-well flat-
bottom plates. 200 µl of Europium solution were added to each supernatant sample, allowed 
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to shake gently at room temperature for at least 15 min and time-resolved fluorometry 
measured in a Wallac Victor2TM multilabel fluorescence plate reader (Perkin-Elmer).  
Data were analyzed using Microsoft Excel. Means of triplicates were calculated and the 
specific lysis calculated using the following formula. 
Percentage specific lysis = (mean release in the presence of T cells- mean minimum release)/ 
(mean maximum release-mean minimum release) X 100 
 
2.2.8.5 Analysis of T cell receptor Vβ chain usage 
cDNA was prepared from T cell lines or clones (RNA isolation and cDNA preparation 
described below) and used as template in 25 separate PCR reactions, which differed in the Vβ 
chain specific primers used. The primers were manufactured by Metabion with sequences 
described (Gussoni et al., 1997).  
The PCR products were separated in an agarose gel, and the products of the PCRs visualized. 
Where required the PCR products were blotted from the gel onto a membrane and hybridized 
with a radioactive Vβ chain gene common region DNA-specific probe. 
 
2.2.9 Preparation of concentrated B95.8 culture supernatant 
Supernatant from B95.8 cells was centrifuged at 1000 X g for 10 min to remove cells and 
cellular debris. Cell free supernatant was then filtered through a 0.8 µm filter and 
ultracentrifuged at 25,000 X g for three hours in a SW28 rotor. The supernatant was removed 
and the virus rich pellet resuspended in 1/20 volume of the original culture supernatant. The 
genomic copy number of this virus concentrate was determined by semi-quantitative real-time 
PCR using primers directed to the BALF5 gene. The virus concentrate used in this work 
contained 4.65 X 108 EBV genome equivalents (geq). For virus inactivation the EBV 
supernatant was heated to 56°C for one hour. Successful inactivation was verified by the 
inability of the heated virus supernatant to transform primary human B cells.  
 
2.2.10 Fixation of cells 
Paraformaldehyde (PFA) fixation was the method used in this work for immunofluorescence 
and antigen presentation studies. Briefly, cells to be fixed were harvested by centrifugation, 
washed three times thoroughly with PBS and then fixed in 0.5% PFA in PBS at room 
temperature for 10 min. Fixed cells were washed at least three times in PBS before 
subsequent use. 
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2.3 Bacteriology and biochemistry materials and methods 
2.3.1 Nutrient media for bacterial culture  
The chemicals were bought from Roche or Merck. 
LB media 
10 g NaCl, 10 g tryptone and 5 g yeast extract dissolved in 1 l deionised sterile water, 
pH adjusted to 7.0, autoclaved.  
SOB media 
20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 2.5 mM KCl, 10 mM MgCl2, and 10 mM 
MgSO4 per liter deionised water, autoclaved. 
SOC media 
SOB media with 0.2% Glucose. 
Super broth media 
35 g tryptone, 20 g yeast extract and 5 g NaCl dissolved per liter deionised water, pH 
adjustment to 7.5, autoclaved. 
LB agar 
10 g NaCl, 10 g tryptone, 5 g yeast extract and 20 g agar dissolved in 1 l deionised 
water, pH adjusted to 7.0, autoclaved and poured into petri dishes (~25 ml/100-mm 
plate).  
 
2.3.2 Storage of bacteria 
For storage, bacteria were frozen at -80°C in 10% glycerol (in LB media).  
 
2.3.3 Preparation of electrocompetent bacteria 
The electrocompetent bacterial strain used in this work was the XL1-Blue MRF (Stratagene). 
Stocks of this strain were plated onto LB agarose plates with tetracycline (working 
concentration of 10 µg/ml) and incubated overnight at 37°C to obtain single colonies. 400 ml 
of LB medium was inoculated with a single colony and incubated in a bacterial shaker to an 
optical density (OD) of 0.8. Bacteria were then centrifuged at 4°C at 2800 X g for 5 min, the 
supernatant discarded and the pellet resuspended in 400 ml of ice cold 10% glycerol. This 
resuspension was centrifuged for 10 min at the same speed and temperature. This wash step 
with 10% glycerol was repeated and the bacterial pellet resuspended in 2 to 4 ml of ice cold 
10% glycerol. In 1.5 ml Eppendorf safe lock tubes, 50 µl aliquots/tube of this final 
resuspension were frozen down by immediately exposing the tubes to liquid nitrogen, and 
stored to -80°C. 
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2.3.4 Bacterial transformation with DNA 
Bacteria were transformed with DNA by electroporation. Appropriate mixtures of 
electrocompetent bacteria and the DNA of interest were pipetted into a 1 mm cuvette and 
pulsed with 1500 V, 25 µF and 100 Ω. After the pulse, bacteria were transferred into a 1.5ml 
Eppendorf tube by pipetting with 1 ml of SOC media. After incubation at 37°C for at least 30 
min the bacteria were pelleted by centrifugation at 2800 X g for 5 min, most of the 
supernatant discarded carefully and the bacterial pellet resuspended in the remaining media. 
This suspension was plated onto LB agarose plates with antibiotics as indicated. 
 
2.3.5 Small scale plasmid preparation 
Small scale plasmid preparation was performed to check single bacterial colonies for the 
plasmid they carried. 4 ml of LB media with appropriate antibiotics were inoculated in snap 
caps with single colonies of bacteria and incubated overnight in a shaker. The next day 
plasmid was extracted from the bacteria using the Jetstar miniprep kit (Genomed). 1 ml of an 
overnight culture was transferred into a 1.5 ml Eppendorf tube and the bacteria pelleted by 
centrifugation on a table centrifuge at 2,800 X g for 5 min. The supernatant was discarded, 
and the pellet resuspended in 100 µl solution E1 (supplemented with RNAse A). Bacterial 
lysis with 100 µl E2 followed after which the whole mix was neutralized with 100 µl 
neutralization solution E3. The mix was then centrifuged at 16,000 X g for 10 min after which 
the clear supernatant was carefully transferred into a new 1.5 ml Eppendorf tube, and the 
DNA precipitated with 70% ethanol. The DNA was pelleted at the bottom of the tube by 
centrifugation (16,000 X g for 15 min). The supernatant was discarded, the DNA pellet air 
dried and subsequently dissolved in an appropriate volume of water or 1 X TE as required.  
1X TE: 10 mM Tris-HCl pH 7.5; 1 mM EDTA in deionised sterile water. 
  
2.3.6 Large scale plasmid extraction 
The basic protocol applied for large scale preparation of plasmid DNA was essentially similar 
to the one used for small scale plasmid DNA preparation. The same solutions were used. 
Larger volumes (400 to 500 ml) of bacterial cultures were grown overnight in a shaker. When 
the ODλ600 reached between 0.8 and 1.0, the bacteria were pelleted by centrifugation at 2,800 
X g for 10 min and the supernatant discarded. The bacteria were then resuspended in 10 ml of 
E1 with RNAse A, lysed with 10 ml of E2 and the lysate neutralized with 10 ml of E3. A step 
of centrifugation allowed precipitates to settle down and low density dregs to float upon a 
clear supernatant. The supernatant was carefully poured onto pre-equilibrated (with 15 ml 
solution E4) maxi-prep columns through a cloth filter in order to avoid floating dregs onto the 
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column. The flow through was discarded and the column washed three times with 20 ml of 
wash solution E5. Following the wash the DNA was eluted of the column with 15 ml of 
elution buffer E6. DNA in the eluate was precipitated with 40% isopropanol final 
concentration and pelleted by centrifugation at 9,300 X g for 15 to 20 min. The pellet was 
washed with 70% ethanol and allowed to air dry after which it was dissolved in an appropriate 
volume of water or 1 X TE as necessary. 
 
2.3.7 Verification of plasmid DNA 
Identity of the plasmid DNA was verified by restriction endonuclease digestion or by 
sequencing. Sequencing was performed by Sequiserve. 
 
2.3.8 RNA isolation and reverse transcription polymerase chain reaction (RT-PCR)  
Total cellular RNA was isolated from cells using the RNeasy -Mini-Kit (Qiagen) according to 
the manufacturer's protocol. Isolated RNA was resuspended in RNAse free water and aliquots 
were frozen at -80°C. 
cDNA was prepared from RNA by using the MuMLV reverse transcriptase (NEB). Reverse 
transcription reactions were set up typically in 25 µl volumes. In an Eppendorf tube 1 μl oligo 
(dT) (Roche) primer was added to 1 to 3 μg total RNA and filled up to 18 µl with RNAse-free 
water. The mix was then heated to 70°C for 10 min and chilled on ice for 30 sec. 
Subsequently, 5 μl 5 X reverse transcriptase buffer, 1 μl 10 mM dNTP mix (Amersham) and 1 
μl reverse transcriptase were added to the tube, mixed by pipetting and incubated at 37°C for 
1 hour.  
PCRs were performed to amplify EBV genes and to amplify T cell receptor Vβ chains 
expressed in T cell lines and clones. As template for the TCR Vβ chain analysis, cDNA 
prepared from T cell lines and clones was used. For the amplification of EBV genes, the 
plasmid 2089 containing the whole B95.8 wild type viral DNA sequence (kindly provided by 
Prof. Wolfgang Hammerschmidt) was used as template. PCR reactions were set up according 
to the suggestion of the manufacturer of the DNA polymerases. If PCR products were to be 
used in subsequent cloning steps, Pfu polymerase was used. The number of PCR cycles varied 
between 20 and 45. PCR reactions consisted of an initial denaturation step at 95°C for 5 min 
followed by the cyclic reactions. Each cycle consisted of a denaturation step at 95°C for 1 min 
followed by a primer annealing step for 1 min at the annealing temperature between 56 and 
62°C depending on the primer pairs used, and an extension step at 72°C 1 to 5 min depending 
on the expected length of the PCR product. Primer pairs used to amplify the coding sequences 
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of defined EBV genes carried recognition sequences for restriction enzymes to facilitate 
cloning of the PCR products into expression plasmids. The sequences of the primers used for 
EBV gene amplification and cloning are shown in the annex. PCR products were separated in 
agarose gels and the PCR products purified out of the gel using the Qiaex II Gel Extraction kit 
(Qiagen).  
 
2.3.9 Separation of DNA fragments by agarose gel electrophoresis  
Separation of DNA fragments was performed in 0.8% to 1.2% agarose gels with 0.4 μg/ml 
ethidium bromide in 1 X TAE by electrophoresis. The agarose content of the gel was 
determined by the size of the DNA band expected; the larger the DNA fragment, the lower the 
agarose content. DNA samples were mixed with 1/5 volume of DNA gel loading buffer 
(0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol, 30% v/v glycerol) and loaded into 
the gel slots. Electrophoresis was performed in the horizontal position with 1x TAE running 
buffer. 1 kb DNA ladder (MBI Fermentas) was used as size standard. For the isolation of 
DNA fragments from agarose gels, the desired fragments were cut out from the gel with a 
clean scalpel and DNA isolated using a Qiaex II Gel Extraction kit (Qiagen) following the 
manufacturer’s instructions.  
50 x TAE: 2M Tris base and 50mM EDTA in deionised sterile water; pH adjusted to 8.5. 
 
2.3.10 Phenol-chloroform extraction and precipitation of DNA  
To remove contaminants from DNA, an equal volume of a mixture of phenol, chloroform and 
isoamyl alcohol (proportions 25/24/1) was added to the DNA solution. The mixture was 
centrifuged for 10 min at 13000 X g to separate the phases. The upper aqueous phase was 
transferred with a pipette into a new 1.5 ml Eppendorf tube, and the DNA in the aqueous 
phase precipitated by the addition of 2 volumes of 100% ethanol and 0.1 volume 3 M sodium 
acetate. After centrifugation at 13000 X g the pellet was washed in 70% ethanol, dried and 
dissolved in deionised sterile water. DNA concentration was measured by UV-
spectrophotometer.  
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2.3.11 DNA restriction  
For DNA restriction 2 to 4 U of the desired restriction enzymes were added to 1 μg of DNA in 
the appropriate restriction buffer. Commercially available buffers and enzymes were used and 
reactions set up as recommended by the manufacturers (NEB or MBI Fermentas). The total 
volume of digestion was 10 X the volume of enzyme added. The restriction mix was 
incubated for 1 to 2 h at the optimal working temperature for the restriction enzyme used.  
 
2.3.12 Blunt ending of digested DNA 
Where necessary, sticky ends of DNA products created by restriction enzyme digest were 
blunt ended. This was done by adding 10 U of T4 DNA polymerase (NEB) and 1 µl of 10 
mM dNTP mix directly to the restriction enzyme digest and incubating the mix for 15 min at 
room temperature. 
 
2.3.13 Ligation of DNA 
DNA fragments with compatible ends were ligated with T4 DNA ligase (MBI Fermentas). A 
3-fold molar excess of insert over vector was used. Typically, 1 U enzyme was used for the 
ligation of 200 ng DNA in a 20 µl reaction mix. Ligations were incubated overnight at 16°C.  
When synthetic linkers were ligated to vectors, the oligonucleotides were first heated to 95°C 
and subsequently allowed to hybridize by slowly cooling the mix to room temperature. 
 
2.3.14 Construction of EBV gene expression vectors and recombinant baculoviruses 
The ORFs of EBV genes were amplified by PCR and cloned into the multiple cloning site 
(MCS) of the pCMV-CHis vector or a modification thereof. The primers were designed based 
on the published B95.8 wild type EBV sequence. In the sense primer the start codon of the 
genes was left out since the vector was prepared by digestion with NcoI and blunt ended with 
T4 polymerase. This created a blunt ended ATG sequence which provided the start codon for 
the inserted genes. The antisense primers contained at the 3`end a restriction enzyme 
recognition sequence not present elsewhere in the gene but present in the multiple cloning site 
of the vector. PCR products digested with this enzyme were purified by gel electrophoresis 
and ligated into the expression vector which had been digested with NcoI, treated with T4 
polymerase, and digested with the same enzyme as the PCR product. The EBV genes cloned 
in this study are listed in table 3.2 of the results section.  
In the pCMV-CHis vector the inserted gene is followed by sequences coding for the antibody 
epitope recognized by the EBNA1-specific monoclonal antibody 1H4 (kindly provided by Dr. 
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E. Kremmer) and for a tag consisting of six histidines. The histidine tag allows to purify the 
the gene products over nickel-agarose beads (described below), and the antibody epitope 
allows to visualize the proteins by Western blot. 
Recombinant baculoviruses were created following the protocol of the manufacturer (BD 
Pharmingen). Briefly, the gene of interest was first transferred from the pCMV-CHis vector 
into a baculovirus transfer vector. This construct was transfected into Sf9 cells along with 
Baculogold DNA to generate recombinant baculoviruses by homologous recombination. The 
plaque assay was used to obtain individual recombinants. Amplified stocks derived from 
different plaques were used to infect Sf9 cells. Histidine-tagged proteins were purified from 
Sf9 cells four days after infection and analysed by Western blot. Virus stocks that led to high 
level expression of the inserted gene were selected, amplified, and used for large scale protein 
production. 
 
2.3.15 Protein expression in eukaryotic cells 
For protein expression in insect cells, approximately 70% confluent Sf9 cells were infected at 
an MOI of 3 to 10. The virus containing medium was replaced with fresh medium after 12 
hours and the cells were allowed to produce protein for 72 to 96 hours. The cells were then 
harvested by centrifugation. 
Transfection of 293T cells with plasmid DNA for protein expression was done using the 
CaPO4 method. For transfection 60-70% confluent cells grown in 140 mm plates were used. 
For one such plate, the cells were first supplemented with 32 ml fresh media and then 8 ml of 
the transfection mix was dropped over the whole surface area of the plate. The 8 ml 
transfection mix consisted of 4 ml 2 X HBS. The rest was a mixture of DNA (80 µg per 
plate), CaCl2 (400 µl of a 2.5 M sterile filtered solution) and chloroquine (40 µl of a 0.5 M 
solution) filled up to 4 ml with water. The transfection mix was prepared by slowly dripping 
the DNA-containing solution into the 2 X HBS while constantly bubbling air with a pipette 
through the HBS solution. The transfection mix was added to the cells within 5 min of 
preparation. 6 to12 hours after transfection, the media was removed and replenished with 
fresh media. The cells were harvested 48 to 72 hours after transfection and pelleted by 
centrifugation. 
2X HBS: 11.9 g HEPES, 16.4 g NaCl and 0.21 g Na2HPO4 in 1 l deionised water; pH adjusted to 7.05; sterile 
filtered. 
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2.3.16 Lysis of protein expressing cells and purification of recombinant protein 
The protein-expressing cells were harvested by centrifugation and 108 cells lysed in 50 ml 
urea lysis buffer. The lysate was centrifuged in order to pellet cell debris and DNA 
complexes, and the clear lysate in the supernatant was transferred to a new 50 ml Falcon tube. 
Next, 300 µl NiNTA agarose beads (Qiagen) were added, and the tubes allowed to rotate 
overnight at 4°C in an overhead rotator. The following day, the tubes were centrifuged, and 
the supernatant discarded. The beads with the bound proteins were washed once with lysis 
buffer. Subsequently, the proteins were eluted using elution buffer. The beads were 
resuspended with 300 µl elution buffer, centrifuged (10,000 X g for 2 min), and the 
supernatant transferred to a new tube. This procedure was repeated twice, and the collected 
supernatant dialysed against PBS and the protein content determined using the Bradford 
reagent. For quantification, known concentrations of bovine serum albumin were used as 
standards. 
Urea lysis buffer: 8 M Urea, 0.1 M NaH2PO4, 0.01 M Tris base, 0.05% Tween 20, 20 mM imidazole dissolved in 
deionised sterile water; pH adjusted to 8.0. 
Elution buffer: 0.5 M imidazole in Urea lysis buffer. 
 
2.3.17 Western blot analysis of proteins 
Eluted proteins were mixed with 1/5 volume of SDS loading buffer and heated to 95°C for 5 
min. Subsequently, the samples were loaded onto 10% polyacrylamide gels. Usually two gels 
were run in parallel of which one was stained with Coomassie blue stain to detect all proteins 
in the eluate. A similar second gel was blotted onto a Hybond P membrane (Amersham). The 
membrane was blocked by letting it swim in Blocking Buffer for at least one hour and then 
incubated in Western buffer with the tag specific antibody (anti-EBNA1 antibody 1H4, kindly 
provided by Dr. Elisabeth Kremmer). After at least two hours of incubation, the primary 
antibody was removed, the membrane washed three times in Western buffer and then 
incubated with a peroxidase conjugated secondary antibody (goat anti rat) again in Western 
buffer. After two hours, the membrane was washed thrice and developed using the ECL plus 
developing solution (Amersham). For size approximations, a pre-stained protein marker 
(Fermentas) was run in at least one lane of the gel. 
SDS loading buffer: 50 mM Tris-HCl (pH6.8), 2% SDS, 0.1% Bromophenol Blue, 10% glycerol. 
SDS running buffer: 3 g Tris base, 14 g glycine and 10 ml 10% SDS filled to 1 l with deionised water. 
Transfer buffer: 4.5 g Tris base, 21 g glycine in 1.5 l of 20% methanol in deionised water. 
Western buffer: 1% skimmed milk powder in TBS (20 mM Tris-Cl, 150 mM NaCl in deionised water; pH 7.5). 
Blocking Buffer: 3% skimmed milk powder in Western buffer. 
Results 42
3. Results 
To investigate breadth and specificity of the EBV-specific T helper cell response, two 
experimental approaches were pursued (Fig 3.1).  
A) 
B) 
 
Figure 3.1. Schematic depiction of the two approaches used to generate EBV-specific CD4+ T cells in vitro.  
CD4+ T cells from the peripheral blood of donors were stimulated every two weeks with either A) autologous 
LCLs generated by EBV infection of B cells in vitro or B) recombinant EBV protein-pulsed autologous PBMC. 
 
First, CD4+ T cell lines were generated by repeated stimulation with the autologous LCL 
respectively. Because LCL express all nine latency proteins of EBV, this approach was 
expected to reactivate T cells with different specificities, and to eventually select T cells 
specific for immunodominant antigens. Second, CD4+ T cell lines specific for individual 
EBV antigens were established by repeated stimulation with protein-pulsed PBMCs. By this 
approach, the breadth of the T helper response against EBV could be analyzed.  
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3.1 MHCII-restricted CD4+ T cell lines were generated by stimulation with 
autologous LCL 
LCL express high levels of MHCI, MHCII, and co-stimulatory molecules. Stimulation of 
peripheral blood T cells with LCL causes massive expansion of reactive CD4+ and CD8+ T 
cells. In order to obtain EBV-specific CD4+ T cell lines, PBMCs were repeatedly stimulated 
with irradiated autologous LCL, and the resulting T cell lines enriched for CD4+ cells by 
magnetic cell sorting (MACS), either by depleting CD8+ cells or by positively selecting 
CD4+ cells. This enrichment was performed after the fifth stimulation, and was repeated at 
least twice within the next five passages. The resulting T cell lines contained more than ninety 
percent CD4+, CD8-, and TCRα/β+ cells (Figure 3.2).  
A) 
B) 
C) 
 
Figure 3.2. FACS analysis of a LCL-stimulated CD4+ T cell line.  
A) Forward and sideward scatter analysis (left) and staining of dead cells with propidium iodide (right). B) 
Analysis of CD4 and CD8 expression by the T cells. The cells were stained with anti-human CD4-PE and anti-
human CD8-FITC (right) or isotype control antibodies (left). C) Staining with anti-human TCRα/β-PE (right) or 
isotype control (left) antibodies. More than 90% of the T cells were CD4 positive, CD8 negative and TCR αβ 
positive.  
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LCL-stimulated T cell lines were generated from 23 individuals including eight IM patients, 
nine healthy virus carriers, one EBV-seronegative adult, and five cord blood donors. The 
MHCII genotypes of the donors and other cell lines used in this work are shown in Table 3.1. 
 
Table 3.1. The HLA-DR, -DQ, -DP genotype of the donors and cell lines used in this work.  
 
CD4+ T cell lines established by LCL stimulation were continuously cultivated for more than 
sixty passages (more than two years). This long term culture of the T cells in vitro permitted 
to analyze them in detail over multiple passages of stimulation.  
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3.2 LCL stimulation led to expansion of CD4+ T cells with different specificities 
To assess MHCII restriction, the different T cell lines were co-cultured with target cell lines 
of known MHCII haplotypes and cytokine secretion by the T cells was measured by ELISA. 
T cell lines from all nine EBV-positive healthy donors and seven out of eight IM patients 
responded consistently against autologous and MHCII-matched, but not against MHCII-
mismatched allogeneic LCL, suggesting that the T cell lines were restricted by self-MHCII 
molecules. Early passage T cell lines usually recognized target cells expressing non-
overlapping sets of self-MHC molecules, indicating that these lines were polyclonal. MHC 
restriction of the same T cell lines at later passages was focused on one or two MHC alleles, 
suggesting that the T cell lines became oligoclonal with repeated stimulations. Figure 3.3 
shows the cytokine response of several T cell lines against autologous and MHCII-matched as 
well as mismatched allogeneic LCL targets.  
 
Figure 3.3. LCL-stimulated CD4+ T cell lines were MHCII-restricted. 
The T cell lines were tested for target-specific IFN-γ secretion using autologous, MHCII-matched and 
mismatched LCL as targets. The T cell lines responded only against autologous (bars shaded light green) and 
MHCII-matched but not MHCII-mismatched allogeneic LCLs. 
 
No MHCII restriction could be assigned to the T cell line IM7 established from IM patient 7 
(IM7). This line failed to show any target-specific cytokine secretion. 
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Cord blood-derived T cell lines from five donors failed to show specific and consistent 
responses against autologous and MHCII-matched LCL. These lines, however, responded 
vigorously against some MHCII-mismatched LCLs, suggesting that these T cells were 
alloreactive. The T cell line established from the EBV-negative healthy adult AR displayed a 
similar pattern of recognition (Figure 3.4) which indicated that LCL-stimulated CD4+ T cell 
lines from EBV-negative donors poorly respond against EBV-positive autologous target cells 
but show a high degree of alloreactivity. 
 
 
Figure 3.4. CD4+ T cell lines from EBV-negative donors fail to show consistent responses against 
autologous LCL.  
T cell lines from two cord blood donors (LA and EK) and from the EBV-negative adult donor AR were tested 
against different targets for cytokine response. The T cell line from donor LA secreted insignificant amounts of 
GM-CSF (<50 ng/ml). The T cell lines from donors EK and AR failed to show autologous LCL-specific 
responses, but recognized MHC-mismatched allogeneic LCLs. Responses against autologous LCLs are shown 
by bars in green. 
 
To assess EBV specificity of the T cell lines established from EBV-seropositive donors, 
partly MHCII-matched EBV-negative BL cell lines and when available in vitro EBV-infected 
convertants of the BL cell lines, were included as target cells in cytokine secretion assays. T 
cell lines from all healthy EBV-positive donors recognized MHC-matched EBV-positive but 
not EBV-negative BL lines, indicating that LCL-stimulated CD4+ T cells from EBV-positive 
individuals are specific for EBV antigens. Representative experiments with T cell lines 
derived from the healthy virus carriers GB and MA are shown in Figure 3.5. The T cell lines 
from four out of seven IM patients behaved similarly in such experiments. Surprisingly, T cell 
lines derived from three IM donors that had also recognized autologous LCL in an MHCII-
restricted fashion in initial assays failed to show EBV-specific responses. These T cell lines 
responded equally well against partly MHCII-matched EBV-positive as well as EBV-negative 
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targets, suggesting that the dominant T cell populations in these T cell lines are directed 
against self-antigens (Figure 3.5).  
 
 
Figure 3.5. All LCL-stimulated CD4+ T cells from EBV-seropositive healthy individuals, but only half of 
the T cell lines from IM patients were EBV-specific.  
T cells from different donors were tested for specific cytokine secretion against autologous (bars in green) and 
allogeneic, MHCII-matched and mismatched EBV-positive and -negative target cells. 
 
3.3 LCL-stimulated, late passage CD4+ T cell lines were oligoclonal 
The recognition of different LCL targets that shared no MHCII molecules by early passage T 
cell lines had indicated that LCL-stimulated T cell lines contained T cells of more than one 
specificity. Even T cell lines that had been stimulated more than 20 times still recognized 
allogeneic EBV-positive target cell lines with non-overlapping sets of MHCII alleles. To 
investigate how many different specificities were still present in late passage T cell lines, T 
cell receptor beta chain (Vβ) expression was analyzed. RNA was extracted from T cell lines 
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at different passages of stimulation, reverse transcribed, and the Vβ chains amplified by PCR 
using sequence-specific primers for the different human Vβ chains. The PCR products were 
separated in an agarose gel, blotted onto a nylon membrane, and hybridized with a Vβ 
common region-specific radioactive probe.  
T cell lines stimulated less than 20 times usually expressed multiple Vβ chains. This pattern 
changed gradually with further rounds of stimulation. After 50 rounds of stimulation, a few T 
cell lines expressed only one, while most of the T cell lines still expressed at least two 
different Vβ  chains, indicating that LCL-stimulated T cell lines remained oligoclonal even 
after almost two years of continuous in vitro culture. The results of such studies on two T cell 
lines are shown in Figure 3.6.  
A) CD4-LCL IM1 p50 
B) CD4-LCL DA p50 
 
Figure 3.6. TCR Vβ chain analysis of late passage T cell lines.  
RNA extracted from T cell lines established from IM patient 1 (IM1) (A) and the healthy EBV-seropositive 
donor DA (B) was reverse transcribed, and TCR Vβ chains amplified by PCR using primer pairs specific for the 
various human Vβ chains. The resulting PCR products were separated in an agarose gel, Southern blotted, and 
hybridized with a TCR Vβ-specific radioactive probe. The different Vβ chains expressed by the T cell lines are 
indicated beneath the autoradiographs. Even after 50 rounds of stimulation (p50), these LCL-stimulated T cell 
lines expressed more than one T cell receptor Vβ chain.  
 
3.4 EBV latency antigens were not the targets of LCL-stimulated CD4+ T cell 
lines 
LCL express up to eight antigenically distinct EBV latency proteins (Küppers et al., 2003). To 
test which of the latent viral antigens was recognized by the LCL-stimulated EBV-specific T 
cell lines, the different latency proteins were recombinantly expressed in a baculovirus 
expression system as histidine-tagged fusion proteins, and purified from virus-infected cell 
lysates over nickel columns. PBMCs of the donors were incubated separately with the 
different recombinant EBV latency proteins. After 24 hours, excess protein was removed by 
washing, and the protein-pulsed PBMCs probed with the autologous LCL-specific CD4+ T 
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cells. As shown in Figure 3.7, all of the T cell lines responded against autologous LCL 
targets, but not against autologous, untreated PBMCs, demonstrating that these lines were 
EBV-specific. Surprisingly, none of the T cell lines responded against any of the latency 
proteins.  
 
 
Figure 3.7. Latent antigens of EBV were not the targets of LCL-stimulated CD4+ T cell lines.  
LCL-stimulated T cells were tested for recognition of latent antigens using PBMCs pulsed with latent proteins as 
targets in cytokine secretion assays. Although all three representative T cell lines responded against autologous 
LCL, no recognition of PBMCs alone, or PBMCs pulsed with any of the latent proteins of EBV was observed.  
 
In control experiments of our group, the protein-pulsed PBMCs were probed with latent 
antigen-specific T cells that had been isolated from peripheral blood of healthy virus carriers. 
These T cells efficiently recognized protein-pulsed PBMC, demonstrating that antigen was 
efficiently presented by the APC (Mautner et al., unpublished data). Thus, although T cells 
specific for latent antigens of EBV are readily detectable in the peripheral blood of healthy 
virus carriers and have been isolated and characterized by several groups (Mautner et al., 
2004; Long et al., 2005), LCL-stimulated EBV-specific T cell lines failed to recognize latent 
antigens of EBV. This might have been either due to inefficient presentation of endogenous 
latency proteins on MHCII or because latent antigen-specific T cells were too few in numbers 
and were therefore dominated by other specificities. These results implied that these T cell 
lines recognized either cellular antigens induced by EBV or viral antigens other than latent 
antigens.  
 
3.5 Late passage LCL-stimulated CD4+ T cells of seropositive donors failed to 
respond against miniLCL 
To discriminate between these possibilities, a genetically engineered EBV strain called 
miniEBV, was used. This viral mutant infects and growth-transforms primary B cells as 
efficiently as the wild-type EBV (Kempkes et al., 1995), and the resulting so-called miniLCL 
Results 50
are phenotypically identical to regular LCL established by infection of B cells with wild-type 
virus (Moosmann et al., 2002). MiniLCLs, however, are deficient in genes and genetic 
elements that are essential for lytic replication of the virus. Consequently, this viral mutant 
cannot reactivate from latency and enter the lytic cycle.  
Since miniLCL present antigen as efficient as regular LCL and express all latency proteins of 
EBV (Moosmann et al., 2002), using them as targets in T cell assays should allow 
determining whether the LCL-stimulated T cell lines were specific for cellular antigens 
induced by the latency proteins of EBV, or recognized viral antigens expressed during lytic 
replication. Therefore, miniLCLs were generated from those donors from which PBMCs were 
available, and probed with the autologous T cell lines.  
Early passage T cell lines responded similarly against LCLs and miniLCLs. Which antigens 
these T cells recognized was not known, but FCS could be excluded as potential antigen 
because miniLCLs grown in human serum were recognized equally well by these T cells. 
Since previous experiments had revealed that LCL-stimulated T cell lines did not recognize 
latent antigens of EBV, the miniLCL-reactive component in earlier passage T cell lines was 
probably recognizing a cellular antigen.  
This pattern of recognition changed profoundly when later passage T cell lines were tested. T 
cell lines stimulated more than 10 to 15 times still responded strongly against autologous 
LCL, but progressively lost miniLCL-reactivity (Figure 3.8). Thus, later passage T cell lines 
turn specific to lytic antigens of EBV or cellular antigens induced by EBV replication.  
 
Figure 3.8. Late passage LCL-stimulated T cell lines failed to respond against miniLCL.  
T cell lines from different donors at different passages of stimulation (indicated on the X-axis) were tested 
against the autologous LCL and miniLCL. In the case of IM patient 1 (IM1) from whom no autologous miniLCL 
were available, a MHC-matched allogeneic LCL and miniLCL were used.  
 
To quantify changes in the reactivity of T cell lines against miniLCL over different passages, 
ELISPOT assays were performed. As shown in Figure 3.9, the T cell line from donor GB at 
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passage 9 responded to the LCL and miniLCL to similar levels while at passage 19 the 
miniLCL-reactivity of the T cell line had vanished.  
 
Figure 3.9. LCL-stimulated CD4+ T cell lines lost miniLCL reactivity upon repeated stimulations.  
The response of the T cell line from donor GB against the autologous miniLCL and LCL were quantified in IFN-
γ ELISPOT assays. A fixed number of 104 T cells at passage 9 and 19 of stimulation were co-cultured with 
titrated numbers of miniLCL or LCL GB cells. The number of target cells recognized were enumerated as spot 
forming units per 104 T cells. At passage 9, the response against the miniLCL and LCL was similar. At passage 
19, however, the response against the LCL was unaltered but the response against the miniLCL had disappeared.  
 
By contrast, the three T cell lines established from IM patients that had failed to show EBV-
specificity in initial assays consistently responded similarly against miniLCLs and LCLs even 
upon long-term culture (data not shown). Again, latent antigens of EBV were not the targets 
of the T cell response, because PBMCs from IM patients pulsed with latency proteins were 
not recognized, suggesting that these lines predominantly reacted against cellular autoantigens 
rather than viral antigens. 
Taken together, these results suggested that LCL-stimulation of CD4+ T cells led to the 
expansion of T cells specific for non-latent EBV or autoantigens. In T cell lines established 
from latently infected healthy virus carriers, the EBV-specific T cells expanded more 
vigorously than autoreactive T cells and dominated the T cell cultures over time. For reasons 
unknown, the proliferative capacity of EBV- and auto-reactive T cells from patients with IM 
appeared to be similar, and the T cell lines were eventually dominated by one or the other 
reactivity.  
 
3.6 MiniLCL-stimulated CD4+ T cells responded against EBV-positive and  
-negative B cell lines to similar levels 
The failure of all LCL-stimulated T cell lines to respond against latent antigens was 
surprising, because all cells in an LCL culture express latency proteins, and CD4+ T cells 
specific for latent antigens of EBV had been described by different groups (Munz et al., 2000; 
Leen et al., 2001; Mautner et al., 2004; Long et al., 2005). Furthermore, these T cells had been 
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shown in some cases to recognize LCLs directly, implying that LCLs should be able to 
expand such reactivities. One possible explanation for these unexpected findings was that 
latent antigen-specific T cells became activated and were induced to proliferate by LCL-
stimulation, but were then overgrown by T cells specific for antigens associated with viral 
lytic replication. According to this scenario, LCL-stimulated T cell lines should display latent 
antigen-specificity if miniLCL were used as stimulators, since the latter do not express 
antigens associated with lytic replication of the virus. To address this model experimentally, 
miniLCL were used to reactivate specific CD4+ T cell memory from the peripheral blood of 
an EBV-seropositive donor from whom latent antigen-specific CD4+ T cells had been 
isolated and characterized in our laboratory (unpublished data). The stimulations with 
miniLCLs were performed as with LCLs. After several rounds of stimulation, the T cell line 
was tested for recognition of the autologous miniLCL, LCL and EBV-negative target cells. As 
shown in Figure 3.10, the T cell line recognized the autologous miniLCL and LCL to similar 
levels and also responded against EBV-negative BL cell lines. This pattern of recognition did 
not change with further rounds of stimulation, indicating that this T cell line was specific for 
autoantigen(s). 
 
 
Figure 3.10. MiniLCL-stimulated CD4+ T cells were specific for autoantigens.  
CD4+ T cells from donor JM were repeatedly stimulated with autologous miniLCL, and the T cells tested at 
passage 15 against autologous miniLCL and LCL, allogeneic LCL and the partly MHCII-matched EBV-negative 
BL cell line BL70 as well as its EBV-positive convertant BL70-B95.8. The T cell line recognized autologous 
and MHCII-matched LCL, autologous miniLCL and EBV-negative and -positive BL cell lines with similar 
efficiency. 
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These results demonstrated that T cells specific for latent antigens of EBV were not 
efficiently expanded by LCL- or miniLCL- stimulation, possibly because peptides derived 
from latent antigens were insufficiently presented on MHCII.  
 
3.7 The targets of LCL-stimulated EBV-specific CD4+ T cells were lytic cycle 
antigens of EBV 
The non-recognition of latent antigens by LCL-stimulated T cell lines and the differences in 
the recognition of LCLs versus miniLCLs suggested that lytic cycle antigens of EBV, or 
cellular antigens induced by lytic replication, were the targets of LCL-stimulated, EBV-
specific CD4+ T cell lines. In fact, CD4+ T cell responses against lytic cycle antigens of EBV 
in the peripheral blood of healthy carriers had been reported before (Landais et al., 2004; 
Wallace et al., 1991). The EBV genome contains more than 90 putative ORFs, but the 
corresponding proteins have not been identified in all cases. In order to identify the antigens 
recognized by the EBV-specific T cell lines, an LCL-stimulated CD4+ T cell line was cloned 
and one of the EBV-specific clones tested by our group in a novel assay developed for the 
identification of antigens recognized by CD4+ T cells (Milosevic et al., unpublished data). 
Using this approach, the antigen recognized by the T cell clone was identified as BNRF1, a 
lytic cycle protein of EBV. These results for the first time provided experimental proof that 
lytic cycle proteins may be the targets of the LCL-stimulated T cell lines. In order to 
characterize the antigens recognized by the LCL-stimulated T cell lines in detail, 35 ORFs of 
lytic cycle genes of EBV (listed in table 3.2) were cloned into a mammalian expression 
vector.  
 
 
Table 3.2. The ORFs of EBV lytic cycle genes cloned and expressed in this work. Shown are the gene 
designations and the lengths of the ORFs.  
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The EBV ORFs were amplified by PCR from B95.8 viral DNA and cloned into the MCS of 
the plasmid pCMV-CHis. The region immediately downstream of the MCS coded for the 
EBNA1 antibody epitope recognized by the monoclonal antibody 1H4, followed by six 
histidines. Expression of the inserted gene was controlled by a cytomegalovirus (CMV) 
promoter/enhancer. After transient transfection of the plasmids in HEK293T cells, fusion 
proteins were created that consisted of an EBV protein followed by the EBNA1 antibody 
epitope and a histidine tag (schematically depicted in Figure 3.11A). This permitted to purify 
the histidine-tagged recombinant proteins over nickel columns and to verify identity and 
integrity of the purified proteins by Western blotting using the EBNA1-specific antibody 
(Figure 3.11B).  
 
igure 3.11. Cloning and expression of EBV lytic cycle genes.  
ammalian expression vector pCMV-CHis. 
ppropriate APCs were pulsed with the recombinantly-expressed EBV lytic cycle proteins 
A) 
B) 
F
A) The ORFs of 35 EBV lytic cycle genes were cloned into the m
Expression of inserted genes was controlled by a cytomegalovirus promoter/enhancer (pCMV) which leads to 
high level expression of the inserted genes in eukaryotic cells. The EBV proteins were C-terminally tagged with 
an EBNA1 antibody epitope followed by six histidines (6X His) that allowed purification of the fusion proteins 
over nickel-agarose beads. B) Eight purified lytic cycle proteins were analyzed by Western blot using the anti-
EBNA1 antibody 1H4. 
 
A
and subsequently probed with the T cell lines. In most experiments, autologous miniLCLs 
were used as APC because earlier experiments had shown that these cells were barely 
recognized by the T cell lines. In those cases where no autologous miniLCLs were available, 
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miniLCLs from partly MHCII-matched donors were used, provided that the LCL of this 
donor was efficiently recognized by the T cells. 
Using this approach, several antigens recognized by the EBV-specific T cell lines were 
identified. While most of the T cell lines recognized one of the lytic cycle antigen tested, 
some late passage T cell lines recognized more than one antigen. This was in accordance with 
results obtained by Vβ chain analyses in earlier experiments showing that LCL-stimulated 
CD4+ T cells lines were oligoclonal. In the case of the T cell line IM1, none of the 
recombinantly expressed proteins was recognized. Because these T cells responded against 
MHC-matched LCL but not miniLCL of the same donor this T cell line most likely 
recognized (an) additional lytic cycle protein(s) that had not been included in this study. 
Representative results of these studies are shown in Figure 3.12. 
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Figure 3.12. The targets of LCL-stimulated CD4+ T cells are lytic cycle proteins of EBV.  
T cell lines from different donors at different passages (indicated as CD4-followed by the autologous stimulator 
LCL and the passage number) were tested in IFN-γ-specific ELISA for recognition of the LCL (green bars), 
miniLCL and miniLCL pulsed with different recombinantly expressed and purified EBV lytic cycle proteins. 
When an autologous miniLCL was not available (IM1 and IM2), a miniLCL derived from a partly MHCII-
matched donor was used provided that the LCL of the donor was recognized by the T cells. For reasons of 
lucidity, only responses against a limited set of proteins are shown.  
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3.8 LCL-specific CD4+ T cell clones were generated and analyzed for their 
specificity 
To analyze composition and specificity of the LCL-stimulated, oligoclonal EBV-specific T 
cell lines in more detail, several of the T cell lines were single cell cloned by limiting dilution, 
and the specificity of the outgrowing clones analyzed. Initially, outgrowing clones were tested 
against LCLs, miniLCLs, and miniLCLs pulsed with lytic cycle proteins identified as the 
antigen recognized by the parental T cell lines. In Figure 3.13, representative results obtained 
with T cell clones from two T cell lines are shown. 
A) B)
 
Figure 3.13. Analysis of single cell clones derived from autologous LCL-stimulated CD4+ T cell lines from 
healthy donor MA (A) and IM patient IM2 (B) in IFN-γ secretion ELISAs.  
The T cell clones were tested for recognition of LCLs, miniLCLs and miniLCLs pulsed with the EBV lytic cycle 
protein identified as targets of the parental T cell line. For testing specificity of the T cell clones from IM2, the 
partly MHC-matched LCL and miniLCL from donor DA were used. 19 clones from the T cell line MA and five 
from the T cell line IM2 were analyzed. The numbers on the X-axis indicate the number of clones showing the 
pattern of recognition. 
 
The parental T cell line MA p17 had responded against the BMRF1- and BNRF1-pulsed 
miniLCL. Consequently, the clones were tested against the LCL MA, miniLCL MA and 
miniLCL MA pulsed with BMRF1 or BNRF1 proteins. Among 19 clones that were analyzed 
from this line in IFN-γ secretion assays, five distinct patterns of recognition were observed. 
Eight of the clones recognized BMRF1, and one recognized BNRF1. Of the remaining clones, 
four responded exclusively against the LCL, and four responded neither against the LCL nor 
against the protein-pulsed or untreated miniLCL. Two T cell clones responded against the 
LCL and also significantly against the miniLCL, whether untreated or pulsed with 
recombinant protein. These results demonstrated that the LCL-stimulated line from donor MA 
contained at least five different specificities. Of these, two were directed against BMRF1 and 
BNRF1. The third that responded against the LCL but not against the miniLCL probably 
Results 59
recognized lytic cycle antigen(s) other than BMRF1 and BNRF1. For the fourth that secreted 
no IFN-γ in response to either the LCL or the miniLCL, the target antigen was not known (see 
section 3.9). The clones that recognized LCL and miniLCL probably represented autoantigen-
specific T cells. These specificities were probably responsible for the background activity of 
the parental line against the miniLCL observed in experiments depicted in Figure 3.12. Since 
the antigens recognized by the last three types of T cells were unknown, it remained unclear 
whether the clones within the same group recognized one or several antigens. 
Essentially similar observations were made with T cell clones obtained from another T cell 
line. Results on the clones obtained from the IM line IM2 are summarized in Figure 3.13b. Of 
the five clones tested, three recognized BXLF2, and the other two most likely recognized (an) 
other lytic cycle antigen(s) because these T cells recognized the MHCII-matched LCL but not 
the miniLCL.  
Taken together, these results suggested that late passage LCL-stimulated T cell lines were 
predominantly, but not exclusively directed against lytic cycle antigens of EBV. Moreover, 
the T cell lines established from different donors recognized different antigens, suggesting 
that the targets of the EBV-specific T helper cell response lack a hierarchy of 
immunodominance. 
Four of the T cell clones generated from donor MA had not secreted cytokines in response to 
autologous LCL, the stimulator cells for the parental T cell line. A similar pattern of apparent 
unresponsiveness had already been observed with the T cell line from IM patient 7, 
suggesting that T cells with this phenotype are not infrequent within LCL-stimulated CD4+ T 
cell lines. Because such T cells have not been described before, neither in the context of EBV 
infection nor in other conditions, attempts were made to characterize these T cells in more 
detail.  
 
3.9 LCL stimulation also expanded CD4+ T cells failing to secrete prototype Th 
cytokines 
To further characterize the non-IFN-γ-, non-GM-CSF-secreting T cells that grew out upon 
LCL stimulation, experiments with the T cell line IM7 and with a clone from the line DA 
were conducted. These T cells could be maintained in culture by stimulation with the 
autologous LCL and IL-2. The T cell line IM7 retained the same phenotype until passage 62 
when further culture of this line was discontinued, suggesting that T cells with such 
specificity may dominate LCL-stimulated bulk cultures. The absence of any detectable IFN-γ 
secretion by these T cells could indicate that the T cells were of Th2 or TR1 subtypes, 
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characterized by the secretion of IL-4 and transformimng growth factor-beta (TGFβ) plus IL-
10, respectively. Therefore, secretion of these cytokines upon co-culture with autologous LCL 
was measured, but again, no target specific secretion of these cytokines could be detected 
(Figure 3.14).  
 
Figure 3.14. LCL-stimulation of CD4+ T cells expands T cells that fail to secrete prototype Th cytokines.  
T cells of this type failed to show cytokine responses against autologous and allogeneic LCL and miniLCL 
targets. The response of the T cell line IM7 against autologous LCL 7 and allogeneic LCL SM, and of clone 1A9 
derived from the T cell line DA against the autologous LCL and miniLCL are shown. 
 
Even upon non-specific T cell activation with PHA, the T cells failed to secrete any of the 
cytokines tested. In an additional set of experiments, the T cells were studied in proliferation 
assays. A constant number of 1x105 T cells was brought out per well in a 96-well plate, either 
alone, with 10 U/ml IL-2, with PHA and IL-2, or with 105 irradiated autologous or allogeneic 
LCL in the presence or absence of PHA and/or IL-2. After 72 hours incubation at 37°C, the 
supernatant was removed and fresh medium with (3H)-thymidine added to the wells. After 24 
hours, the wells were washed and (3H)-thymidine incorporation measured with a 
scinticounter. The T cell line IM7 as well as the clone 1A9 proliferated best in the presence of 
IL-2 and proliferated only minimally in response to either the autologous or allogeneic LCL 
in the absence of IL-2. PHA alone or in the presence of autologous or allogeneic LCL did not 
induce proliferation (data not shown).  
These results indicated that CD4+ T cells obtained by LCL stimulation might comprise a T 
cell population that does not belong to the classical T helper cell types. Further studies are 
required to characterize these T cells and identify their role(s) in the immune response to 
EBV. 
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3.10 LCL-specific CD4+ T cells were detected at low precursor frequencies in 
peripheral blood 
The results of the previous experiment raised the question as to how many CD4+ T cells in 
the peripheral blood were specific for EBV lytic cycle antigens. Since lytic cycle antigens and 
not latent antigens of EBV were the major targets of CD4+ T cells obtained by LCL 
stimulation, this question could be addressed by comparing responses against LCL versus 
miniLCL. As suggested by previous experiments, LCLs stimulate autoantigen- and lytic cycle 
antigen-specific T cells whereas miniLCLs activate only autoantigen-specific T cells. 
Therefore, IFN-γ ELISPOT assays were performed on T cells from the peripheral blood of 
available donors from whom miniLCLs as well as LCL had been established. First, PBMC 
were enriched for CD4+ T cells by depleting CD8+ and CD19+ cells and subsequently added 
to titrated numbers of LCL and miniLCL targets. In order to exclude the detection of FCS-
reactive T cells, targets grown in human serum were used. By subtracting the miniLCL-
reactive from the LCL-reactive T cell population, an average of 0.5% to 1% of the peripheral 
blood CD4+ T cells were calculated to be specific for lytic cycle antigens of EBV. 
 
Figure 3.15. Quantification of peripheral blood CD4+ precursor frequencies reactive against lytic cycle 
antigens of EBV.  
Titrated numbers of CD4-enriched PBMCs were tested in IFN-γ ELISPOT assays against a fixed number of 103 
autologous LCL or miniLCL targets cultivated in human serum. The results of experiments with CD4+ cells 
from the peripheral blood of the three EBV-positive healthy donors DA, TK and JM are shown.  
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3.11 The lytic antigen-specific CD4+ T cell response was directed against several 
antigens 
The apparent lack of any pattern of immunodominance among lytic cycle antigens together 
with the observations that about 0.5% to 1% of peripheral blood CD4+ T cells were specific 
for EBV lytic cycle antigens, while individual lytic antigen-specific T cells were present at 
much lower frequencies (data not shown), suggested that the EBV-specific T helper response 
might be directed against several lytic cycle antigens simultaneously. To investigate whether 
healthy virus carriers maintain memory responses against several lytic cycle antigens of EBV, 
the CD4+ T cell response against the EBV immediate early protein BZLF1 and two EBV late 
lytic cycle proteins, BLLF1 and BALF4, was studied. BLLF1 was chosen since EBV-infected 
individuals are consistently positive for antibodies to this membrane antigen, also referred to 
as EBV glycoprotein gp350/220 (Thorley-Lawson et al., 1982). BALF4 is another membrane 
glycoprotein (gp110) known to elicit an antibody response (Jilg et al., 1994). BZLF1 is a lytic 
cycle transactivator that has been shown to induce CD8+ T cell responses (Elliott et al., 
1997). While BALF4 and BZLF1 recombinant proteins were expressed in and purified from 
293T cells, BLLF1 was expressed in and purified from Sf9 cells by baculovirus infection 
because this protein was poorly expressed in 293T cells. Purified protein was then used to 
reactivate specific T cells from the peripheral blood of five healthy EBV carriers. Starting at 
passage four, T cells were tested for specificity in GM-CSF ELISAs. After six rounds of 
stimulation, the CD4+ T cell lines showed reactivity against the protein against which they 
had been raised, but not against control proteins which had been purified under identical 
conditions (Figure 3.16).  
 
 
Figure 3.16. Peripheral blood of healthy EBV carriers contained CD4+ T cell memory against more than 
one EBV lytic cycle proteins.  
Specificity of the CD4+ T cell lines established from donor JM was tested after six to eight rounds of stimulation 
by GM-CSF ELISA. PBMCs pulsed for 24 hours with different recombinant proteins were used as target cells. 
The T cell lines responded selectively against PBMCs pulsed with the stimulator but not irrelevant protein.  
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3.12 BLLF1-, BZLF1- and BALF4-specific T cell clones were generated from T 
cell lines and characterized  
To characterize these T cells in more detail, the T cell lines from donor JM were cloned by 
limiting dilution. All outgrowing T cell clones were found to be CD4-positive, CD8-negative, 
d with recombinant proteins 
e same MHCII molecule. Six representative 
 
onor JM. 
pitopes were synthesized and pulsed at various concentrations onto autologous PBMCs, and 
TCRα/β-positive and TCRγ/δ-negative (data not shown). RT-PCR analysis in combination 
with Southern blot hybridization of the variable part of the TCR Vβ chain confirmed that the 
single cell outgrowths were monoclonal CD4+ T cell cultures (data not shown). The T cell 
clones obtained from each of the three T cell lines expressed two different Vβ chains, 
indicating that the clones derived from two different precursors.  
To identify the restricting MHCII molecules of the different clones, PBMCs from various 
donors sharing different MHCII alleles with donor JM were pulse
and probed with the T cells. The antigenic epitopes recognized by the T cells were identified 
using a novel method for direct epitope identification (DEPI) established in our laboratory 
(Milosevic et al., 2005).  
Not unexpectedly, all T cell clones specific for a given protein expressing the same Vβ chain 
recognized the same epitope presented on th
clones specific for two different epitopes in each of the three antigens were chosen for further 
analysis. These clones and their characteristics are summarized in Table 3.3.  
 
Table 3.3. Characterization of six EBV lytic cycle antigen-specific CD4+ T cell clones established from
d
 
In order to define the affinities of the T cells for their cognate antigen, peptides spanning the 
e
recognition by the T cell clones were assayed in cytokine secretion experiments. As shown in 
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Figure 3.17, the various clones recognized target cells pulsed with cognate peptide at 
concentrations as low as 1 to 3 nM, while responses to control peptides were not observed 
even at much higher concentration.  
 
 
 
 
Figure 3.17. The T cell clones recognized antigen with high specificity.  
ognate (shaded forms) and control 
ere removed by washing, and the 
 addition to GM-CSF, all lytic cycle antigen-specific CD4+ T cell clones secreted IFN-γ but 
f these T cells in peripheral blood, IFN-γ ELISPOT 
Autologous PBMCs were pulsed with the indicated concentrations of c
peptides (open forms) for two hours. Subsequently, unbound peptides w
peptide-pulsed PBMCs probed with the T cell clones. After 24 hours, IFN-γ secretion by the T cells was 
measured by ELISA.  
 
In
no IL-4 upon specific target recognition. This pattern of cytokine secretion implied that the T 
cell clones were Th1 type CD4+ T cells.  
To determine the precursor frequencies o
assays were performed. PBMC of donor JM were enriched for CD4+ T cells by magnetic 
depletion of CD8+ T cells. Subsequently, 105 CD4+ enriched PBMCs were incubated with 2 
µM of cognate or control peptides and the number of IFN-γ secreting cells determined by 
ELISPOT. No specific signals above background were detected with any of the peptides, 
suggesting that the frequency of these T cells in the peripheral blood is less than 1 in 104, 
which is considered the detection limit of this assay. Earlier experiments had shown that 
approximately 0.5% to 1% of all peripheral blood CD4+ T cells in healthy virus carriers are 
specific for lytic cycle antigens of EBV. The successful reactivation of memory T cell 
responses against three of three lytic cycle antigens in one donor further underlined that T 
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helper cells specific for many different lytic cycle antigens probably existed in the peripheral 
CD4+ T cell pool. 
 
3.13 BLLF1- and BLLF4-specific CD4+ T cell clones responded against LCLs and EBV-
positive BL cell lines, but not against miniLCLs 
To test whether the EBV lytic cycle protein-specific T cell clones recognized EBV-infected 
cells autologous LCL and miniLCL were probed with the T cells. All four T cell clones 
specific for peptides derived from the two viral glycoproteins BLLF1 and BALF4, but not the 
two BZLF1-specific T cell clones recognized autologous and MHCII-matched allogeneic 
LCL (Figure 3.18). 
 
 
Figure 3.18. EBV glycoproteins BLLF1- and BALF4-specific but not BZLF1-specific CD4+ T cells 
recognized EBV-positive target cells directly.  
The six different lytic cycle antigen-specific T cell clones were probed with autologous and partly MHC-
matched allogeneic LCLs and IFN-γ secretion was subsequently measured by ELISA. The glycoprotein-specific 
T cells recognized LCLs in a MHCII-restricted manner, whereas BZLF1-specific T cells failed to recognize 
target cells directly. PBMCs pulsed with recombinant protein were used as positive controls in these 
experiments. 
 
None of the T cell clones responded against autologous or MHCII-matched allogeneic 
miniLCLs (Figure 3.19A), indicating that lytic viral replication is necessary for the 
recognition of EBV-infected cells by lytic cycle antigen-specific T cells.  
EBV-positive BL cells are more permissive for lytic replication than LCL (Rickinson and 
Kieff, 2001). To test whether glycoprotein-specific T cells also recognized these tumor cell 
targets, EBV-positive BL cell lines expressing the restricting MHC molecules were probed 
with the glycoprotein-specific T cell clones. As shown in Figure 3.19B, EBV-positive BL cell 
lines were recognized as efficiently as LCL by BLLF1- and BALF4-specific T cells. 
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A) B) 
 
Figure 3.19. Recognition of EBV-positive target cells by glycoprotein-specific CD4+ T cells was dependent 
on viral lytic replication. 
A)Lytic cycle protein-specific T cells were tested for recognition of autologous and allogeneic LCL and 
miniLCL pairs. The BLLF1- and BALF4-specific T cell clones recognized autologous and MHCII-matched 
LCLs, but not miniLCLs. The BZLF1-specific T cells recognized neither of the targets. B) Glycoprotein-specific 
T cells also recognized MHC-matched EBV-positive (BL30 B95.8, Ag876) but not -negative BL cell lines 
(BL30). Autologous LCLs served as positive controls while EBV-negative or MHCII-mismatched BL cell lines 
served as negative controls.  
 
3.14 Antigen was transferred between cells in culture 
The difference in the recognition of LCLs and miniLCLs by the T cells implied that 
recognition of EBV-infected cell lines by lytic cycle protein-specific T cells is dependent on 
lytic replication. Recognition of LCL cultures by BLLF1-specific CD4+ T cells had been 
noted before, and was found to be mediated by endogenous and exogenous presentation of the 
antigen following spontaneous lytic cycle replication in a small proportion of cells in LCL 
cultures (Lee et al., 1993). However, the strength of the signal detected in cytokine secretion 
experiments was surprising not only in view of the low percentage of usually less than 1% of 
cells in an LCL culture that spontaneously become permissive for lytic replication (Rickinson 
and Kieff, 2001), but also of the fact that cells undergoing lytic replication show greatly 
reduced expression of MHC molecules and secrete gp42, an EBV glycoprotein that has been 
shown to inhibit T helper cell recognition (Keating et al., 2002; Ressing et al., 2005). To gain 
further insight into antigen expression, processing and presentation of glycoproteins, the level 
of spontaneous lysis in the LCL JM was investigated. 105 LCL or miniLCL JM were fixed 
and labeled with monoclonal antibodies directed against BZLF1 and BLLF1. Expression of 
both proteins was indicative of active lytic replication. After staining of the cells with a 
fluorescence-labeled secondary antibody, the cells were inspected under an UV-fluorescence 
microscope. No staining was seen with the miniLCLs JM, whereas less than 1% of the cells in 
LCL JM were positive for expression of both proteins (data not shown).  
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To quantify the number of cells in LCL cultures recognized by the T cells, a fixed number of 
105 per well antigen-specific T cells were used in IFN-γ ELISPOT assays using serial 
dilutions of autologous LCL, miniLCL or MHCII-mismatched LCL (control) targets. As 
shown in Figure 3.20A, a surprising 20% of LCL cells were spotted out by glycoprotein-
specific T cells. MiniLCL and control LCL-containing wells showed background number of 
spots. No spots above background were detected with BZLF1-specific T cells, irrespectively 
of the target cells used (data not shown). 
The discrepancy in the number of cells that stained positive for BZLF1 and BLLF1 in the 
immunofluorescence studies and the number of cells positive in the ELISPOT experiments 
suggested that antigen was transferred between cells, and peptides presented by bystander 
cells. To address this possibility, mixing experiments were performed. The autologous 
miniLCL was co-cultured with a MHCII-mismatched allogeneic LCL for 24 hours and then 
probed with the T cells. Neither the autologous miniLCL, nor the MHCII-mismatched LCL 
was recognized on its own. However, the cell mix was recognized by all glycoprotein-specific 
T cell clones but not by the BZLF1-specific T cell clones (Figure 3.20 B). 
A) B) 
 
Figure 3.20. EBV glycoprotein antigens were transferred between cells in culture. 
A) Serial dilutions of autologous LCL, miniLCL, and MHC-mismatched LCL cells were incubated with 105/well 
BLLF1-1H2 T cells, and the number of target cells recognized by the T cells was determined by IFN-γ 
ELISPOT. The T cells recognized nearly 20% of autologous LCL cells while addition of miniLCL or allogeneic 
LCL cells resulted in background numbers of spots. B) MiniLCL JM co-cultured with the MHC-mismatched 
allogeneic LCL DA, but not miniLCL DA was recognized by glycoprotein-specific but not BZLF1-specific T 
cells, indicating that a transfer of glycoprotein antigens has occurred between these cell types in culture. 
MiniLCL JM incubated with the cognate antigen was included as specificity control.  
 
3.15 Released viral particles efficiently transferred antigen between cells 
The sources of the transferred antigens were either fragments of cells in which EBV had 
replicated or released virus particles. To test the latter possibility, virus purified from 
supernatant of the B95.8 marmoset cell line by ultracentrifugation was pulsed onto the 
miniLCL JM that was subsequently probed with the T cells. Virus-pulsed miniLCL targets 
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were efficiently recognized by the BLLF1 and BALF4-specific T cells (data not shown), 
demonstrating that viral particles were capable of transferring antigen.  
Viral particles could have transferred antigen in at least two different ways: (i) indirectly by 
superinfecting miniLCL followed by lytic replication in infected cells, and (ii) directly by 
transferring glycoproteins present in the virions. Expression of glycoproteins after induction 
of lytic replication requires 48 to 72 hours (Kieff and Rickinson, 2001). Because in the above 
mentioned experiments, glycoprotein-specific T cells had recognized miniLCL pulsed with 
viral concentrate for only 12 hours, superinfection as the mode of antigen transfer appeared 
unlikely. Even by taking into account that the virus-pulsed target cells were co-cultured with 
the T cells for additional 24 hours, this did not provide enough time for synthesis, processing 
and presentation of glycoproteins.  
To assess the kinetics of antigen presentation in more detail, the miniLCL was pulsed with 
virus supernatant for various periods of time. Subsequently, the virus-pulsed cells were fixed 
with paraformaldehyde to terminate antigen presentation, and probed with the glycoprotein-
specific T cells. These experiments demonstrated that miniLCL cells incubated with viral 
supernatant for only 12 hours were already efficiently recognized by the T cells (Fig. 21). 
Thus, viral particles appeared to transfer antigen directly and superinfection of target cells 
was not required. These findings were corroborated in additional control experiments where 
the viral concentrate was first heat inactivated at 56°C for half an hour, and then used to pulse 
the miniLCL. MiniLCL cells pulsed with heat-inactivated virus were recognized as efficiently 
as miniLCL cells pulsed with untreated virus, ruling out superinfection as mode of antigen 
transfer. The efficiency of this virus inactivation protocol was verified by its inability to 
immortalize primary B cells. 
 
Figure 3.21. Viral particles transferred EBV glycoprotein antigens between cells.  
The autologous miniLCL was pulsed with heat-inactivated purified EBV particles (hi-EBV), or was mixed with 
MHCII-mismatched LCL for different periods of time as indicated. Glycoprotein-specific T cells recognized the 
miniLCL pulsed with virus and co-cultured with a MHC-mismatched LCL with similar kinetics. 
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The miniLCL co-cultured with the MHC-mismatched LCL DA in cell mixing experiments 
was recognized by the T cells with a similar kinetics (Figure 3.21), providing further evidence 
that viral particles transfer antigen between cells in the form of structural proteins present in 
virions. 
The efficient recognition of the miniLCL co-cultured with allogeneic LCL, however, was 
surprising, because LCL supernatant is known to contain few infectious virus particles. To 
assess efficiency of this antigen transfer, the concentration of EBV genome equivalents (geq) 
in the viral supernatant was determined. The miniLCL was pulsed with increasing amounts of 
geq and subsequently probed with glycoprotein-specific T cells.  
A) B)
 
Figure 3.22. Presentation of virus supernatant-derived antigen was a very efficient process and involved 
processing in the endosomal /lysosomal compartment. 
 A) To determine the efficiency of the presentation of virus-derived antigens, miniLCL JM were pulsed with 
limiting concentrations of virus supernatant as indicated on the X-axis and probed with glycoprotein-specific T 
cells. BLLF1- as well as BALF4-specific T cells recognized the miniLCL pulsed with as little as 1 geq of virus 
per cell. B) MiniLCL JM was pulsed with virus for twenty-four hours in the absence or presence of chloroquine 
or leupeptin, fixed with paraformaldehyde, and then probed with glycoprotein-specific T cells (BLLF1-1H2 and 
BALF4-A9). MiniLCL cells incubated alone and incubated with virus supernatant in the absence of inhibitors 
served as negative and positive controls, respectively. Chloroquine and leupeptin both blocked the presentation 
of virus supernatant-derived antigens. 
 
As shown in Figure 3.22A, miniLCL incubated with as little as 0.8 geq per cell were 
recognized by BLLF1- and BALF4-specific T cells. This demonstrated that the uptake and 
subsequent presentation of virion antigens is extremely efficient. When target cells were 
treated with chloroquine or leupeptin during incubation with viral supernatant, T cell 
recognition was almost completely abrogated, indicating that antigen processing occurred in 
the lysosomal compartment (Figure 3.22B). Chloroquine and leupeptin both inhibit lysosomal 
degradation (Honey and Rudensky, 2002).  
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3.16 Presentation of virion proteins was depending on receptor-mediated uptake 
of viral particles by B cells 
Infection of B lymphocytes by EBV is receptor-mediated, and involves adsorption of 
gp350/220 to CD21, followed by aggregation of CD21 on the plasma membrane and the 
internalization of EBV into cytoplasmic vesicles (Carel et al., 1990; Tanner et al., 1987). To 
test whether this receptor-mediated uptake of EBV was essential for efficient presentation of 
virion antigens, EBV supernatant was incubated with the anti-gp350/220 monoclonal 
antibody 72A1. This antibody had been shown to prevent infection of B cells by EBV (Janz et 
al., 2000). Preincubation of viral concentrate with this antibody almost completely abrogated 
subsequent recognition of virus-pulsed miniLCL cells by glycoprotein-specific T cells. T cell 
recognition was not affected when miniLCL cells were pulsed with a viral supernatant that 
had been preincubated with a control isotype antibody (Figure 3.23A).  
A) B)
C) D)
 
Figure 3.23. Presentation of virion-derived antigens was receptor-mediated.  
A) MiniLCL JM were pulsed with untreated or pretreated (with an anti-gp350 antibody (AB) or an isotype 
control antibody (Iso)) virus supernatant and probed with glycoprotein-specific T cells. Anti-gp350 antibody 
pretreatment of virus supernatant abrogated the T cell response. B) MiniLCL, DC and PBMC JM were pulsed 
with virus supernatant (B) or recombinant BLLF1 protein (C) as indicated on the X axes for 24 hours and then 
probed with BLLF1-1H2 T cells. MiniLCL cells and PBMCs, but not dendritic cells were able to present virion 
antigens to T cells, but all three APC types presented exogenous antigen on MHCII with similar efficiency. D) 
PBMC JM were separated into CD19+ and CD19- populations, and the two populations pulsed separately with 
virus supernatant. Only the CD19+ population was able to present virion-derived antigens to BLLF1-1H2 T 
cells. 
Results 71
These results suggested that antigen presentation was dependent on receptor-mediated virus 
uptake. Consequently, only antigen presenting cells expressing CD21 should have been able 
to present virion antigens on MHCII. To test this supposition, EBV supernatant was pulsed 
onto the autologous miniLCL, monocyte-derived DCs and PBMCs. As shown in Figure 
3.23B, miniLCL cells and PBMCs, but not DCs were able to present virion antigens to T cells 
under these experimental conditions. Of note, DCs efficiently stimulated the T cells when 
pulsed with BLLF1 peptides and, importantly, when incubated with purified BLLF1 protein, 
demonstrating that uptake, processing and presentation of exogenous antigens was not 
impaired in these cells. In fact, of all cell types tested, DCs presented exogenous antigens 
most efficiently on MHCII (Figure 3.23C). To investigate which cell population within 
PBMCs was able to present virion-derived antigens, B cells were isolated from PBMCs using 
anti-CD19 microbeads and magnetic sorting. CD19+ and the CD19-depleted PBMC fractions 
were then incubated with virus supernatant and probed with T cells. As shown in Figure 
3.23D, the CD19-positive population, but not the CD19-depleted cell fraction was able to 
present virion antigens to T cells.  
 
3.17 Cell fragments and proteins released through lysis of cells barely contributed 
to the amount of antigen transferred 
These experiments illustrated that virus particles could transfer antigen, but did not exclude 
that under in vitro culture conditions, cells undergoing lytic replication or their remnants were 
a major source of antigen. Although the lack of LCL recognition by BZLF1-specific T cells 
suggested that the amount of antigen released by lysed cells was insufficient for T cell 
stimulation, the levels of expression of the virion proteins BALF4 and BLLF1 were likely to 
exceed that of the transcription factor BZLF1. Therefore, released virion proteins might have 
reached levels sufficient for T cell detection. Because DCs were incapable of receptor-
mediated uptake of virion-derived antigens, DCs were used to assess to what extent released 
proteins and cell debris contributed to the transfer of antigen. Autologous DC were co-
cultured with MHC-mismatched LCL cells and then probed with the lytic antigen-specific T 
cells None of the T cell clones recognized the DCs even after extended periods of co-culture, 
demonstrating that cells debris or released proteins contributed insignificantly, if at all, to the 
transfer of antigen (Figure 3.24).  
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Figure 3.24. The amount of antigen released from lytically infected cells was insufficient for T cell 
recognition.  
MiniLCL JM and DC JM were cultured either alone or together with the MHCII-mismatched LCL DA (ratio 
1:1) for 24 hours. After the co-culture, the cells were probed with the BLLF1-1H2 T cells and cytokine secretion 
determined 24 hours later by ELISA. MiniLCLs JM and DCs JM  pulsed with the cognate protein were included 
as controls.  
 
3.18 EBV glycoprotein-specific CD4+ T cells inhibited the proliferation and 
generation of LCL in vitro 
To assess direct effector functions of the virion-specific T cells on the growth of EBV-
infected target cells, LCL JM and miniLCL JM were brought out in round-bottom 96-well 
plates in serial dilutions from 104 to 30 cells/well, with or without 104 monoclonal T cells, and 
proliferation of the cultures followed over time. The GFP-specific CD4+ T cell clone 3A2, 
also established from donor JM, was included as a control (Nimmerjahn et al., 2003). Wells 
were checked weekly for media exhaustion and were refed as necessary. After four weeks, the 
cultures were assayed microscopically for the outgrowth of cells, and CD19 staining 
demonstrated that the outgrowing cells were exclusively B cells (data not shown). As 
compared to irrelevant GFP-specific T cells, proliferation of LCL JM but not miniLCL JM 
was strongly impaired in the presence of glycoprotein-specific T cells (Figure 3.25A). 
Approximately 10-fold higher numbers of LCL were required to achieve continuous 
proliferation of the cells than in control wells. By contrast, proliferation of miniLCL was not 
affected by the glycoprotein-specific T cells. These experiments suggested that virion-specific 
T cells may play an important role in limiting virus spread by inhibiting or eliminating B cells 
that have become infected by EBV.  
The next set of experiments therefore sought to investigate whether glycoprotein-specific T 
cells could hinder the generation of a LCL in vitro. PBMCs from donor JM were depleted of 
CD4+ and CD8+ T cells by magnetic sorting and were subsequently infected with B95.8 
virus. After 24 hours, the cells were washed to remove free virus, and plated at serial dilutions 
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in 96-well microtiter plates together with 104 glycoprotein-, BZLF1-, or GFP-specific T cells. 
Cultures were maintained by weekly refeeding and were assayed for LCL outgrowth after 
four weeks. By that time, outgrowth was immediately apparent from microscopic inspection 
of the wells, and CD19 staining confirmed that the outgrowing cells were of B cell origin and 
not surviving T cells. Figure 3.25B presents the results of one such experiment, expressed as 
the minimum input cell number at which outgrowth of LCL occurred. Compared to control 
wells to which GFP-specific T cells had been added, approximately tenfold higher numbers of 
T cell-depleted PBMC were required to obtain LCL outgrowth. By contrast, addition of 
BZLF1-specific T cells had no inhibitory effect.  
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Figure 3.25 EBV glycoprotein-specific but not the transcription factor BZLF1-specific CD4+T cel
in
A) Decreasing numbers (104 to 30) of autologous LCL or miniLCL JM were plated in 96-well plates in the 
absence or presence of a fixed number (104) of BALF4-, BZLF1-, BLLF1- or GFP-specific CD
donor JM. After one month of culture, the wells were assayed for B cell proliferation by staining for CD19. The 
Y-axis shows the minimum starting number of LCL cells required to achieve a proliferating culture in the 
presence of T cells as x-fold the minimum number required in the absence of T cells. Co-culture of LCL JM, but 
not miniLCL JM, with BALF4- or BLLF1-specific T cells increased the minimum number of cells necessary for 
proliferation five- to tenfold. BZLF1- and GFP-specific T cells neither affected the proliferation of LCL nor 
miniLCL cells. B) 106 CD19+ primary B cells from donor JM were incubated with wild-type EBV for two 
hours. Subsequently, excess virus was removed by washing and the cells plated in 96-well round bottom plates 
in decreasing numbers starting form 104 down to 30 in the presence or absence of a fixed number of 105 T cells. 
The Y-axis depicts the x-fold minimum number of B cells plated to obtain a proliferating LCL culture with 
reference to the number of B cells required in the absence of T cells. GFP- and BZLF1-specific T cells did not 
inhibit LCL outgrowth, while in the presence of BALF4- and BLLF1-specific T cells ten- to fifteen fold higher 
numbers of B cells were required. 
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3.19 EBV glycoprotein-specific CD4+ T cells were lytic and used the granule 
exocytosis pathway to exert their effector functions 
The inhibitory effect of the glycoprotein-specific T cells on proliferation and outgrowth of 
LCL raised the question by which mechanism the T cells exerted that function.  
A) B) 
C) 
 
Figure 3.26. EBV glycoprotein-specific CD4+T cells were cytolytic by the granule exocytosis pathway. 
A) MiniLCL JM incubated with no peptide, with the cognate peptide, or a control peptide, were probed with 
BALF4-B5 T cells in an europium release cytotoxicity assays. The X-axis shows the different effector to target 
(E:T) ratios used in the assays and the Y-axis the specific lysis at the corresponding ratios. Antigen-specific 
killing of up to 70% was observed at an E:T ratio of 10:1. B) BLLF1- and BALF4-specific T cells were assayed 
for target-specific perforin release in ELISPOT assays against miniLCL JM pulsed with 2 µM cognate or control 
peptides. A fixed number of 104 BLLF1-1D6 or BALF4-A9 T cells were co-cultured with titrated numbers 
(3x103 to 102) of peptide-labeled miniLCL. Between 8% and 15 % of cognate peptide-labeled but not control 
peptide-labeled targets were recognized by glycoprotein-specific T cells. C) Target-specific granzyme B release 
by BALF4- and BLLF1-specific T cells as measured in ELISA. MiniLCL JM labeled with either cognate or 
control peptides were used as targets. The glycoprotein-specific T cells secreted IFN-γ as well as granzyme B 
specifically upon antigen recognition. 
 
To test whether the T cells were able to lyse target cells upon recognition, cytotoxicity was 
measured in europium release assays. 106 miniLCL cells were either left untreated or labeled 
with 2 µM of different peptides for two hours. The cells were then washed to remove 
unbound peptides and labeled with BATDA reagent. After 15 minutes at 37ºC, the cells were 
washed thoroughly and dead cells removed by Ficoll gradient centrifugation. 5x103 live cells 
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in 100 µl culture medium were plated per well of a V-bottom plate. Subsequently, T cells in 
100 µl culture medium were added at effector to target ratios from 10:1 to 1:1. After three 
hours incubation at 37ºC, 40 µl of the supernatant was collected and Europium solution 
added. Time-resolved fluorometry was measured and the specific lysis calculated as described 
(section 2.2.8.4). As shown in Figure 3.26A, the BALF4-B5 T cells killed targets pulsed with 
the cognate but not control peptide.  
The rapid cytolysis by the T cells implied that granule exocytosis was involved in this process 
(Lieberman, 2003). Therefore, perforin ELISPOTs and granzyme B ELISAs were performed, 
using miniLCL cells labeled with cognate and control peptides as targets. For ELISPOT 
assays, decreasing numbers of target cells were co-incubated with a fixed number of 104 T 
cells. For the granzyme B ELISA, 105 T cells were incubated with the same number of target 
cells, and the granzyme B in the supernatant measured after 24 hours. As shown in Figure 
3.26B and 26C, glycoprotein-specific T cells released granzyme B and perforin upon specific 
target recognition. These experiments demonstrated that the glycoprotein-specific T cells 
lysed target cells by the granule exocytosis pathway. 
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4. Discussion 
 
Improved immunotherapeutic approaches against EBV-associated PTLD depend on the 
identification of the relevant immunodominant T cell antigens 
In infected B cells, EBV is able to establish different types of latency characterized by the 
expression of different sets of latent cycle proteins (Rickinson and Moss, 1997). Infected B 
cells in immune competent hosts express only few or no latent viral antigens at all which 
allows the virus to evade immune recognition and elimination and to persist for life in the 
infected host (Williams and Crawford, 2005). During primary infection and in 
immunocompromised patients, eight antigenically distinct latent cycle proteins are expressed 
which cause growth-transformation of the infected B cell (Gottschalk et al., 2005). 
Uncontrolled proliferation of these cells in immunosuppressed transplant patients may lead to 
the development of EBV-associated PTLD (Moss and Rickinson, 2005). 
The adoptive transfer of donor-derived EBV-specific T cell lines generated by repeated 
stimulations of peripheral blood T cells with autologous LCL cells has been shown to prevent 
and cure PTLD in BMT patients (Heslop et al., 1996; Bollard et al., 2004). With current 
protocols, the generation of sufficient numbers of EBV-specific T cells for clinical application 
takes at least a few months (Gottschalk et al., 2005). Since PTLDs often progress rapidly, 
such T cell lines would have to be prepared prophylactically for all patients at risk which is 
not possible on a routine basis. To attain a broader clinical application of this T cell therapy, 
alternative approaches have to be developed that allow to establish EBV-specific T cell lines 
faster, even after tumor manifestation. The direct isolation of specific T cells from peripheral 
blood by recently developed methods such as MHC tetramer technology and cytokine 
secretion and capture assay (Bakker and Schumacher, 2005; Mathioudakis et al., 2002) would 
obviate lengthy procedures of LCL generation and repeated rounds of T cell stimulation and 
shorten the time required to prepare such T cell lines. Such approaches, however, are 
dependent on the knowledge of the relevant immunodominant T cell antigens. 
The immunodominant targets of the CD8+ T cell response to EBV are well characterized 
(Rickinson and Moss, 1997). Although CD4+ T cells are recognized as important component 
of the antiviral immune response, the EBV-specific T helper cell response is still poorly 
defined (Khanna and Burrows, 2000). By using two complementary approaches, this work 
attempted to investigate breadth and immunodominance of the EBV-specific T helper cell 
response. In the first approach, the immunodominant antigens recognized by repeatedly LCL-
stimulated, oligoclonal EBV-specific T cell lines were defined. In the second approach, the 
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breadth of the EBV-specific T helper cell response was assessed by stimulating CD4+ T cells 
with autologous PBMCs pulsed with single recombinant proteins of EBV.  
 
CD4+ T cell lines generated from EBV-negative donors failed to show EBV-specificity 
LCL-stimulated CD4+ T cell lines were established from twenty-three individuals and 
maintained in culture for more than fifty passages. Cord blood-derived T cell lines and the T 
cell line from an EBV-negative adult failed to show EBV-specificity even at late passages. 
Initially, these T cell lines responded against autologous and allogeneic LCL without 
displaying a clear pattern of MHCII-restriction. With further rounds of stimulation, responses 
against autologous LCL disappeared and erratic responses against allogeneic LCL suggested 
that the T cell lines were predominantly alloreactive. In attempts to characterize LCL-reactive 
cord blood leucocytes, Moretta et al. had previously identified CD4+ T cells that participate in 
the innate response against EBV (Moretta et al., 1997). When cord blood leucocytes were 
stimulated in vitro with LCL, the resulting cell lines contained NK cells and CD4+ T cells 
that secreted IL-2 upon LCL stimulation, but the specificity of these T cells had not been 
examined. Non-EBV-specific CD4+ T cell lines generated by LCL stimulation of PBMC 
from EBV-seronegative children had also been reported by others (Savoldo et al., 2002). 
These authors also described a CD4+ T cell line that they had established from an EBV-
negative adult by four rounds of LCL stimulation. The T cells specifically lysed autologous 
LCL but not PHA T cell blasts. The authors argued that the cytolytic effect is possibly 
mediated by cross-reactive T cells. Viral antigen-specific T cells that recognize antigens from 
other viruses by molecular mimicry had indeed been described (Welsh et al., 2004). Notably, 
the T cell line from the EBV-negative adult included in our study also responded against 
autologous LCL at early passages. After additional rounds of stimulation, however, this line 
became alloreactive, indicating that T cells putatively cross-reacting against LCL were lost 
from LCL-stimulated T cell cultures over time.  
 
CD4+ T cell lines established from EBV-seropositive donors recognized EBV and 
autoantigens 
Unlike T cell lines from EBV-negative donors, T cell lines established from the peripheral 
blood of all EBV-positive healthy donors and seven out of eight IM patients were MHCII-
restricted, and all T cell lines from EBV-positive healthy adults were EBV-specific as 
demonstrated by their response against EBV-positive, but not against EBV-negative targets. 
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Of the seven MHCII-restricted T cell lines from patients with IM, four were EBV-specific 
whereas three responded equally well against EBV-positive and EBV-negative targets.  
This high prevalence of non-EBV-specific responses was surprising because MHC tetramer 
analyses have demonstrated that up to 50% of the CD8+ T cells in peripheral blood of IM 
patients are specific for a single EBV antigen (Callan et al., 1998), and antibody responses 
against viral proteins also peak during acute infection (Rickinson and Kieff, 2001). Although 
CD4+ T cells do not expand as dramatically as CD8+ T cells during acute infection (Macallan 
et al., 2003), these results implied that a robust EBV-specific T helper cell response is induced 
in IM patients. Since humoral responses depend on T cell help, EBV-specific T helper cells 
must have developed at the time when the patients presented in the hospital and when IM was 
diagnosed serologically. Furthermore, the strong antiviral antibody response observed in IM 
patients implied that the magnitude of EBV-specific T helper cell response during the acute 
phase of infection is probably similar to or even exceeds the response during the persistent 
phase of infection. If this was indeed the case, then the lack of EBV-specificity observed in 
about half of the T cell lines established from patients with IM could either be due to a more 
vigorous expansion of autoreactive than EBV-specific CD4+ T cells during acute infection, or 
to the expansion of T helper cells specific for EBV antigens that are not presented by LCL. 
CD4+ T cells specific for BZLF1, for example, have been detected in three of three healthy 
virus carriers and these T cells failed to recognize LCL. Furthermore, BZLF1-specific T 
helper cell have also been described in patients with IM (Precopio et al., 2003), indicating that 
BZLF1-specific T cells expand during primary infection. Moreover, BZLF1 appears to be an 
immunodominant target of the CTL response during IM (Steven et al., 1997). Because all 
LCL-stimulated T cell lines from latently-infected healthy virus carriers recognized LCLs but 
not miniLCLs, both scenarios imply that T helper cells specific for EBV antigens presented 
on LCLs either expand less vigorously during acute infection or contract less dramatically 
during convalescence than T cells specific for autoantigens or EBV antigens that are not 
efficiently presented by LCLs. Consequently, the relative frequencies of autoreactive and 
EBV-specific T cells in the peripheral blood of IM patients should vary during the course of 
the illness, and the time of blood drawing may impact on the specificity of LCL-stimulated T 
cell lines established from IM patients.  
An overproportional expansion of autoantigen-specific T cells during acute infection might 
also explain the appearance of heterophile antibodies and raises the intriguing possibility that 
these T cells might also contribute to the control of the viral infection. To gain further insight 
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into the role of the various CD4+ T cell specificities in establishing protective immunity 
against EBV, experiments were performed to define the antigens recognized by these T cells.  
 
EBV-specific T cell lines failed to recognize latent cycle antigens of EBV 
Although LCLs express all latent cycle antigens of EBV, none of the LCL-stimulated T cell 
lines recognized any of these antigens. This was again unexpected because LCL-stimulated 
CD8+ T cell lines target latent antigens of EBV (Rickinson and Moss, 1997), and CD4+ T 
cells specific for latent antigens of EBV have been isolated from healthy virus carriers by 
different groups (Munz et al., 2000; Leen et al., 2001; Mautner et al., 2004; Long et al., 2005). 
These findings raised two questions. First, why did latent antigen-specific CD4+ T cells not 
expand upon stimulation with LCL cells and second, what if not the latent antigens were the 
targets of LCL-stimulated EBV-specific CD4+ T cells? The failure of LCL-stimulated T cell 
lines to recognize latent antigens of the virus either indicated that latent antigen-specific T 
cells were present at lower frequencies than other EBV antigen-specific T cells, or that latent 
antigen-derived peptides were presented less efficiently on MHCII. Since miniLCL-
stimulated T cells from a healthy virus carrier failed to show EBV-specificity, the second 
possibility appeared more likely. This notion was further supported by experiments showing 
that most of the latent antigen-specific CD4+ T cells that had been isolated from this donor 
did not respond against latently EBV-infected cells (Mautner et al., 2004 and unpublished 
results). Whether the presentation of latency protein-derived peptides on MHCII is actively 
inhibited by the virus or whether the level of viral protein expression is too low for T cell 
recognition is not known and needs to be addressed in further studies. 
 
Autoantigen-specific T helper cells are an integral part of the CD4+ T cell response to EBV 
infection 
Since LCL-stimulated CD4+ T cell lines did not recognize EBV latency antigens, the antigens 
recognized by early passage T cell lines on miniLCLs were probably autoantigens. Although 
this reactivity declined over subsequent rounds of stimulation and became undetectable in late 
passage T cell lines, almost all LCL-stimulated CD4+ T cell lines showed miniLCL-reactivity 
after ten passages, i.e. five months of in vitro culture. The T cell lines used to treat PTLD 
patients have usually been stimulated less than ten times with the autologous LCL (Gottschalk 
et al., 2005). Therefore, such adoptively transferred T cell lines probably contained 
autoreactive T cells. What fraction of the T cell population is autoantigen-reactive appears to 
vary between individuals, as suggested by the variable responses of LCL-stimulated T cells 
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against miniLCL. The clinical significance of LCL-reactive, autoantigen-specific CD4+ T 
cells is not known. In a recent study, autoreactive CD4+ T cells were identified as important 
effectors in LCL regression assays (Gudgeon et al., 2005). In that study the authors infected 
unseparated, CD4- or CD8-depleted PBMCs with EBV in vitro and assessed LCL outgrowth 
from EBV-transformed B cells. Because the cells that mediated regression in CD8-depleted 
PBMCs were found to be CD4+ T cells that specifically recognized LCL and miniLCL cells, 
but not latency antigens of EBV, the authors inferred that these T cells recognized 
autoantigens. Whether and how autoantigen-specific T cells contribute to regression of EBV-
positive lymphomas in vivo is not known. The failure of these putative autoreactive T cells in 
the study by Gudgeon et al. to recognize EBV-negative B cell blasts implied that the antigens 
recognized by these T cells are induced by EBV. However, the autoantigen-reactive T cell 
lines in our study also recognized EBV-negative BL cell lines, indicating that the transformed 
phenotype per se rather than EBV confered T cell recognition. Whether the antigens 
recognized by the T cells were ubiquitously or B cell-specifically expressed is currently under 
investigation. If the latter was the case, then such autoantigen-reactive T cells might not only 
have a protective role in EBV immunity, but might also play a role in the immune response 
against EBV-negative B cell malignancies.  
 
EBV-specific T helper cell lines from healthy virus carriers responded predominantly against 
lytic cycle antigens  
The autoreactive component present in all early passage LCL-stimulated T cell lines gradually 
declined over further rounds of stimulation, and late passage T cell lines from all healthy virus 
carriers and from about half of the IM patients responded only against LCL but not against 
miniLCL. This pattern of recognition indicated that the antigens recognized by late passage T 
cell lines were derived from lytic cycle proteins of EBV. During lytic replication, 
approximately 80 viral proteins are expressed (Kutok and Wang, 2006). To identify the 
antigens recognized by the EBV-specific T cell lines, 35 EBV lytic cycle proteins were 
recombinantly expressed, and miniLCL pulsed with the purified recombinant EBV proteins 
used to screen late passage LCL-stimulated CD4+ T cell lines. At least nine different lytic 
cycle antigens were recognized by the seven T cell lines analyzed. Most T cell lines 
responded strongly against one or two antigens. In addition, some lines also responded weakly 
against presumably subdominant antigens. Two cell lines neither responded against any of the 
35 lytic cycle proteins, nor against any of the latent cycle proteins. Because both T cell lines 
responded against LCL but not miniLCL cells, the antigens recognized by these T cells were 
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probably other lytic cycle antigens that had not been included in this study, or autoantigens 
induced by viral replication. 
 
Structural proteins were the immunodominant targets of the EBV-specific T helper cell 
response 
The nine EBV antigens identified as dominant targets of the CD4+ T cell response from 
different individuals included the tegument protein BNRF1, the early proteins BALF2 and 
BMRF1, the viral IL-10 homologue BCRF1 and the glycoproteins BALF4, BXLF2, BVRF2, 
BXRF1, and BORF1.  
Except for three targets, namely BMRF1, BALF2, and BCRF1, all other antigens were 
derived from structural proteins of the virus. Responses against each of the three non-
structural proteins were detected once and in different T cell lines, and always in conjunction 
with a structural protein as a second target. These results indicated that perhaps structural 
antigens of the virus comprise the major group of targets of LCL-stimulated CD4+ T cells. 
The tegument protein BNRF1 was recognized by three of the EBV-specific T cell lines tested 
which raised the possibility that BNRF1 is a common and immunodominant target of the 
CD4+ T cell response to EBV. Indeed, CD4+ T cells specific for this antigen have been 
established in our laboratory from some more individuals in the meantime (Adhikary, 
unpublished data). Of note, the various BNRF1-specific T cells were restricted by different 
MHCII molecules, suggesting that BNRF1 is an immunodominant antigen over a broad range 
of HLA class II alleles. BNRF1 is not the most abundant viral protein expressed in lytically 
infected cells, and no CTL responses against this protein have been described. Why this 
protein elicits strong CD4+ T cell responses, therefore, remains to be determined. 
Studies on single cell clones isolated from the LCL-stimulated T cell lines confirmed and 
extended the results of earlier experiments in which TCR Vβ chain expression was analyzed. 
These experiments not only demonstrated that late passage T cell lines were indeed 
oligoclonal, but also showed that T cells present in these lines recognized different antigens, 
and in some cases also displayed different phenotypes. Most of the single cell outgrowths 
recognized lytic cycle antigens, verifying the dominance of lytic cycle antigen specificities in 
EBV-reactive CD4+ T cell lines. Besides the lytic antigens recognized by the parental cell 
line, some of the isolated T cell clones responded against LCL but not against miniLCL or 
miniLCL cells pulsed with any of the recombinantly expressed EBV proteins, suggesting that 
these T cells were specific for additional lytic cycle antigens. Further studies with the 
complete set of lytic cycle proteins, or genetic approaches like the DANI method developed in 
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our group for the direct identification of MHCII-restricted antigens (Milosevic et al., 
unpublished results), are required to define the complete set of immunodominant targets of 
the EBV-specific T helper cell response. 
 
LCL-stimulated CD4+ T cell lines included T cells of non-Th1 or Th2 subtype 
Some T cell clones isolated from LCL-stimulated T cell lines, and the T cell line established 
from patient IM7 failed to secrete prototype Th1 or Th2 cytokines (IFN-γ and IL-4, 
respectively) in response to either autologous or allogeneic LCL. The T cell line IM7 
proliferated in response to autologous LCL and IL-2 and retained this non-Th1/Th2 
phenotype until in vitro culture was discontinued after more than 50 passages. Although the 
antigen(s) recognized by this T cell lines remained unknown, the frequent isolation of such T 
cells from various LCL-stimulated T cell lines indicated that LCL-stimulation promotes the 
expansion of T cells with this phenotype. Whether these T cells belong to the TR1 suppressor 
subtype characterized by the secretion of TGF-β (Roncarolo et al., 2001) or to the recently 
identified T helper cell subtype with autoaggressive potential characterized by the secretion of 
IL-17 (Harrington et al., 2005) or to a completely new subtype of T helper cells, remains to be 
determined. As long as no effector functions have been defined, the role of these T cells in the 
immune response to EBV remains elusive. 
 
In healthy virus carriers the CD4+ T cell response is directed against a broad set of lytic 
cycle antigens 
To assess the breadth of the lytic cycle antigen-specific T helper cell response, protein-pulsed 
PBMC were used to reactivate T helper cells from peripheral blood of healthy virus carriers. 
BZLF1 and BLLF1 (also referred to as gp350) were chosen as target antigens because T 
helper cell responses against these antigens had been detected earlier in peripheral blood of 
patients with IM and healthy virus carriers, respectively (Precopio et al., 2003; Ulaeto et al., 
1988). In addition, the glycoprotein BALF4 (also referred to as gp110) was included in this 
analysis because humoral responses against this antigen had been described (Jilg et al., 1994). 
T cells specific for these antigens were generated from PBMC of five out of five EBV-
positive carriers but not from PBMC of an EBV-negative adult used as control. Of the three 
proteins tested, only BALF4 had been identified as target of LCL-stimulated T cell lines, 
indicating that the EBV-specific T helper cell response is directed against a broader set of 
lytic antigens than that identified by the LCL-stimulation approach. For the purpose of 
characterizing the BZLF1-, BALF4- and BLLF1-specific T cells in more detail, the T cell 
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lines from one EBV-seropositive individual were cloned by limiting dilution and six 
representative clones specific for two different epitopes in each of the three antigens were 
chosen for further analysis  
 
Virion-derived antigens were efficiently presented on MHCII following receptor-mediated 
uptake of released viral particles 
Although all clones recognized their cognate antigenic peptide with similar avidity (1 to 3 
nM), only T cells specific for the glycoproteins BLLF1 and BALF4, but not for the 
transcription factor BZLF1, recognized autologous as well as MHCII-matched allogeneic 
EBV-infected target cells. MiniLCL were not recognized by any of the T cells, suggesting 
that T cell recognition was dependent on sporadic lytic replication occurring in a low 
percentage of cells in culture. However, the percentage of cells recognized by the 
glycoprotein-specific T cells was substantially higher than those positive for lytic cycle 
proteins in immunofluorescence studies. Co-culture experiments of HLA-mismatched LCLs 
and HLA-matched miniLCLs indicated that antigen was transferred from one cell type to the 
other. Additional experiments provided several lines of evidence that the transferred antigen 
was derived from released virions.  
First, miniLCL cells pulsed with purified virus preparations were recognized by the T cells, 
demonstrating that virions can serve as source of antigen. Because miniLCL cells pulsed with 
heat-inactivated virus were still recognized, T cell recognition did not depend on productive 
infection of target cells. Of note, virus supernatant had been utilized before as source of 
antigen to reactivate and expand BLLF1-specific T cells. In fact, these were the first EBV-
specific T helper cell clones isolated and characterized in vitro (Wallace et al., 1991). The 
authors showed that these T cells were able to recognize LCL presenting endogenous and 
exogenous antigen on MHCII, but further implications of such recognition in the control of 
EBV infection were not addressed.  
Second, antigen was most efficiently transferred to B cells, and antigen transfer could be 
blocked by a BLLF1-specific monoclonal antibody which had been shown to prevent EBV 
infection of B cells (Wendtner et al., 2003), suggesting that antigen uptake was receptor-
mediated. Importantly, this antibody treatment not only prevented subsequent recognition by 
BLLF1-specific but also by BALF4-specific T cells, further adding to the notion that the 
antigens presented were derived from virions and not from released proteins.  
Third, the failure of BZLF1-specific T cells to recognize LCL cells, and the failure of 
BALF4- and BLLF1-specific T cells to recognize autologous DCs co-cultured with HLA-
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mismatched LCL cells, demonstrated that the amount of antigen released by dead or dying 
cells was not sufficient for T cell activation. The failure of BZLF1-specific T cells to 
recognize endogenous antigen in cells that had become permissive for viral replication might 
be the consequence of inefficient access to the endogenous antigen presentation pathway(s) 
(Zimmerman et al., 2003), or might be related to immune evasion strategies evolved by EBV 
to prevent immune recognition of lytically infected cells (Keating et al., 2002; Ressing et al., 
2005).  
Interestingly, CD4+ T cells specific for the lytic cycle protein BHRF1 had been reported to 
recognize a similarly high percentage of cells in LCL cultures as the glycoprotein-specific T 
helper cells described here (Landais et al., 2004). However, pathway(s) of antigen 
presentation had not been investigated in that study, and a similar transfer of antigen by viral 
particles appears unlikely because BHRF1 is not a constituent of virions (Johannsen et al., 
2004).  
 
Virus uncoating renders newly infected B cells vulnerable to T helper cell recognition 
The observation that mainly B cells, whether primary or EBV-infected, present virion proteins 
most efficiently implicated a protective role of such T cells in controlling spread of infection. 
Importantly, glycoprotein specific T cells recognized virus-pulsed target cells as early as 
twelve hours after incubation. This is before the EBV genome has circularized and before 
EBNA2, the protein essential for primary B lymphocyte growth transformation, is expressed 
(Alfieri et al., 1991). This implied that glycoprotein-specific T cells can recognize target cells 
that are internalizing virus.  
EBV infection of B lymphocytes is initiated by BLLF1 adsorption to CD21 on the B cell 
plasma membrane, followed by BXLF2 mediated envelope fusion with the cell membrane and 
nucleocapsid exocytosis into the cytoplasm (Tanner et al., 1987; Carel et al., 1990). During 
this process of virus uncoating, proteins of the viral envelope are probably retained at the cell 
membrane, as indicated by the higher percentage of cells positive for BLLF1 than for BZLF1 
in immunofluorescence experiments (Lee et al., 1993). Since cell membrane proteins 
efficiently access the MHC class II processing and loading compartment, T helper cells 
specific for envelope antigens might be able to detect EBV-infected cells before viral latency 
is established.  
This receptor-mediated virion uptake and subsequent presentation of glycoprotein-derived 
peptides on MHC class II was extremely efficient. BALF4- and BLLF1-specific T cells were 
able to recognize miniLCL cells incubated with less than one EBV geq per cell. Thus, virion 
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proteins retained at the cell surface during virus uncoating render newly EBV-infected B cells 
vulnerable to immune attack by CD4+ T cells specific for virion proteins. This mechanism of 
immune surveillance may not be limited to EBV, but may also apply to other coated viruses 
infecting MHC class II-positive target cells. 
 
Glycoprotein-specific T helper cells might play a role in preventing virus spread during 
persistent infection and in the control of EBV-positive tumors 
The glycoprotein specific CD4+ T cells described here were of Th1 type and were able to 
inhibit the proliferation of LCL in vitro. Importantly, these T cells were also able to prevent 
the outgrowth of a LCL from primary B cells infected with EBV in vitro, implicating a role of 
such T cells in diminishing the pool of EBV-infected B cells in vivo. Consistent with this, 
subsidence of T cell surveillance following immunosuppression is often associated with 
increased viral shedding in the throat, and higher numbers of EBV-infected B cells in the 
peripheral blood (Babcock et al., 1999; Baldanti et al., 2000). In BMT and SOT recipients, 
PTLD incidence correlates with the severity of immunosuppression. In PTLD as well as in 
BL, lytic replication has been observed at the site of tumor development (Montone et al., 
1996; Tao et al., 1998). Thus, glycoprotein-specific Th cells may not only aid in controlling 
persistent infection, but may also play a role in the immune control of EBV-associated 
malignancies.  
As compared to blood or LCL cultures, diffusion is impeded in solid tumors leading to the 
sequestration and accumulation of viral progeny within tumors. Because the transformed cells 
in PTLD are considered as in vivo correlate of LCL, these cells are expected to take up 
released virions with similar efficiency. Also, BL cells express the principal EBV receptor 
CD21 and have retained the ability to process exogenous antigen through the MHCII pathway 
for presentation to CD4+ T cells (Khanna et al., 1997). Because antigen presentation on 
MHCI is severely impaired in BL cells (Staege et al., 2002), CD4+ T cells may play an 
important role in the immune response against this tumor.  
In BL cells, the only viral latency protein expressed in vivo is EBNA1. Although EBNA1-
specific Th1 type CD4+ T cells have been shown to kill type III BL cells (Paludan et al., 
2002), it is not known whether type I BL cells are also recognized by these T cells. 
Furthermore, recognition of endogenous antigen by EBNA1-specific CD4+ T cell clones has 
been observed in some (Munz et al., 2000; Voo et al., 2002), but not in other studies (Khanna 
et al., 1997; Leen et al., 2001) and is still a matter of contention (Long, et al, 2004; Mautner, 
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et al, 2004). Therefore, the antitumoral efficacy of EBNA1-specific T helper cells is still 
unresolved.  
This work provided first evidence for the recognition of type I BL cells by glycoprotein-
specific CD4+ T cells in a MHCII-restricted manner. Therefore, glycoprotein-specific T 
helper cells may play a critical role in the immune response against this tumor. Evidences in 
support of this concept had been obtained in preclinical models. Injection with purified 
BLLF1 or infection with vaccinia virus expressing BLLF1 had been shown to protect 
cottontop tamarins against a lethal, lymphomagenic EBV challenge (Morgan et al., 1988; 
Morgan et al., 1997). Although BLLF1 had been identified as the dominant target of the 
neutralizing antibody response in humans (Thorley-Lawson et al., 1982), protective immunity 
in these and other studies did not always correlate with the presence of virus-neutralizing 
antibodies, inferring a role for BLLF1-specific cell-mediated responses in disease protection 
(Wilson et al., 1996). In fact, more recent studies in our group demonstrated that 
glycoprotein-specific CD4+ T helper cells can inhibit the proliferation of BL cells in vitro. T 
helper cell recognition of newly EBV-infected B cells following receptor-mediated cell 
adhesion, penetration and uncoating as described in the present study may provide a 
mechanistic explanation for these findings. Thus, the targets of the EBV-specific T helper cell 
response may not be limited to a small set of latent cycle proteins expressed in these tumors, 
but may also include antigens transferred by virions.  
 
Upon antigen recognition, glycoprotein-specific T cells lysed target cells by secreting 
perforin and granzyme B 
Cytotoxic CD4+ T cells specific for the viral protein EBNA1 have been reported to kill target 
cells by the Fas-FasL pathway (Nikiforow et al., 2003). The glycoprotein-specific T cells 
described here lysed their targets by using the granule exocytosis pathway. Previous studies 
had already suggested that this pathway is used by T helper cells specific for herpesviruses, 
including CMV and EBV (Khanolkar et al., 2001; van Leeuwen et al., 2004). More recent 
studies, however, implied that CMV-specific but not EBV-specific CD4+ T cells were able to 
use this pathway (Amyes et al., 2003; Appay, 2004). The detection of perforin and granzyme 
B-mediated killing of target cells by glycoprotein-specific CD4+ T cells in this work not only 
provided experimental evidence for the existence of EBV-specific cytolytic CD4+ T cells, but 
also added to the importance of CD4+ T cells as direct effectors in the control of EBV 
infection.  
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Non-structural proteins were presented on MHCII by different pathways 
The finding that structural antigens of EBV were efficiently presented on MHCII following 
receptor-mediated virion uptake may explain why most LCL-stimulated T cell lines targeted 
structural proteins. Recent experiments of our group with T cell clones specific for additional 
virion proteins including BNRF1 confirmed that recognition of LCLs by these T cells is 
dependent on antigen transfer by virions (Mautner et al., unpublished results). The antigens 
recognized by LCL-stimulated T cell lines also included non-structural lytic cycle proteins of 
EBV. How these antigens were presented on MHCII is not known. In the case of BCRF1, the 
viral homologue of IL-10, efficient presentation is probably mediated by binding of BCRF1 to 
the IL-10 receptor, followed by the internalization and processing of the complex in the 
endosomal/lysosomal compartment. BALF2, a single-stranded DNA binding protein, and 
BMRF1, a DNA polymerase processivity factor, have also been detected in virions 
(Johanssen, et al, 2004), suggesting that the presentation of these antigens is also receptor 
mediated. However, preliminary experiments suggest that LCL-recognition by T cells specific 
for these antigens is not dependent on virion transfer. Whether these antigens were presented 
endogenously by cells that have entered the lytic cycle or exogenously by bystander B cells 
that took up released protein from dead cells is currently not known. The elucidation of the 
presentation pathway(s) will be important to understand why T cells specific for these 
antigens recognize LCL, while T cells specific for the transactivator BZLF1 fail to do so.  
 
Whether lytically infected cells are recognized by glycoprotein-specific T helper cells is not 
known 
EBV lytic cycle proteins are grouped into immediate early, early and late antigens depending 
on the time of appearance during lytic replication. Once late proteins start appearing the 
infected cells go into lysis (Kieff and Rickinson, 2001). Therefore, immediate early and early 
lytic cycle proteins should have access to the antigen presentation machinery.  
This concept is supported by recent results on the CTL response to lytic cycle proteins of 
EBV (Pudney et al., 2005). In this work the authors compared the efficiency of recognition of 
LCL cells by CD8+ T cells specific for immediate early, early, and late antigens. Although 
the T cells responded similarly to peptide-pulsed target cells, the late antigen-specific CD8+ T 
cells responded only very poorly against LCL cells that had become permissive for lytic 
replication. These findings suggested that at the time when late antigens are expressed, the 
antigen presentation function of EBV-infected cells is impaired.  
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Whether CD4+ T helper cells specific for late antigens of EBV are able to recognize cells that 
entered the lytic cycle, and whether this recognition limits virus production is not known. The 
described reduction in MHCI and MHCII expression on lytically infected cells and the 
secretion of gp42, a glycoprotein interfering with antigen recognition by CD4+ Th cells 
(Keating et al., 2002; Ressing et al., 2003), suggest that CD4+ T cell recognition of cells in 
the lytic cycle is also impaired. Experimental access to this question is difficult, because 
antigen transfer following sporadic lytic replication in LCL leads to T cell recognition of 
latently infected bystander B cells, concealing any recognition of lytically infected cells. With 
the development of recombinant DNA technologies that allow to genetically manipulate EBV 
(Delecluse and Hammerschmidt, 2000), viral mutants can be created that may facilitate to 
address this important immunological question. For instance, LCLs established with a viral 
mutant that is unable to enter the lytic cycle spontaneously, but in which lytic replication can 
be induced, may be instrumental for clarifying this issue.  
 
Approximately 1% of CD4+ T cells in the peripheral blood of healthy virus carriers are EBV-
specific 
The average precursor frequency of EBV-specific T cells in the peripheral blood of healthy 
virus carriers was found here to range between 0.5% and 1%. By using APCs pulsed with 
lysate from EBV-infected cells and measuring intracellular IFN-γ response in CD4+ T cells 
from peripheral blood, Amyes et al. had found that the frequency of EBV-specific CD4+ T 
cells was between undetectable to 1.26% (mean 0.34%) (Amyes et al., 2003). Although the 
results from both studies were similar, they probably underestimated the true precursor 
frequencies for different reasons.  
First and foremost, composition and concentration of EBV proteins in the commercial lysate 
used by Amyes et al. had been poorly defined. Therefore, it remains unclear whether 
sufficient amounts of all EBV proteins were present in the lysate for subsequent detection by 
antigen-specific T helper cells. In our own experiments, DCs mixed for over 24 hours with 
allogeneic LCL cells failed to activate structural antigen-specific CD4+ T cells, indicating 
that the amount of protein released from dying cells was not sufficient to activate these T 
cells. Even though the percentage of lytically-infected cells in the commercial cell lysate was 
presumably much higher than the low percentage of LCL cells that had spontaneously entered 
the lytic cycle in our experiment, the concentration of late cycle proteins in cell lysates might 
be limiting, because structural proteins are rapidly incorporated into virions and released in 
the cell culture supernatant (Kieff and Rickinson, 2001).  
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Second, as the authors showed, the lysate contained distinct proteins in huge amounts (e.g. 
BMRF1, BZLF1 and LMP1). These amounts clearly exceed what is expected in the 
physiological setting and may thus lead to the activation of low-avidity and potentially cross-
reactive T cells.  
Third, although the same cellular source of antigen was used, the activation of alloreactive, 
autoreactive and cross-reactive T cells by the commercial lysate is expected to differ from 
donor to donor and therefore may add to the high variability in precursor frequencies.  
Fourth, the contribution of FCS in the commercial lysate and consequently the activation of 
FCS-reactive T cells to the measurements is not clear. False positive FCS-, autoantigen-, allo-, 
and cross-reactive responses are excluded when LCLs and miniLCLs are used to measure the 
frequency of EBV-specific T helper cells in the peripheral blood. However, only T cells 
specific for antigens presented on LCLs will become activated with this approach which 
probably includes all structural and some non-structural proteins of EBV, but excludes most 
of the latency proteins, BZLF1, and probably the majority of early lytic cycle proteins.  
Fifth, because both approaches used IFN-γ secretion as read-out, EBV-specific Th2 and Treg 
cells which had been detected in healthy virus carriers (Voo et al., 2005; Sun et al., 2002) 
were omitted. If the non-Th1/Th2 type of T cells described in this work also recognized EBV 
antigens, the average percentage of EBV-specific T helper cells in peripheral blood of healthy 
virus carriers is probably even more than 1%. This is probably still much lower than the EBV-
specific CD8+ T cell response where single T cell specificities may already account several 
percent of the peripheral CD8+ T cell population (Tan et al., 1999). This imbalance in 
precursor frequencies perhaps contributes to the observed dominance of CD8+ T cells over 
CD4+ T cells in LCL-stimulated mixed T cell cultures.  
 
CD4+ and CD8+ T cells may synergize in preventing virus spread during the persistent 
phase of EBV infection 
The level of antigen expression and lytic replication vary during the lifetime of an EBV-
infected individual. Following primary infection, infected B cells express all latency proteins 
of EBV, and some infected cells enter the lytic cycle and produce infectious virus (Rickinson 
and Kieff, 2001).  
Immune control of these cells is believed to be mediated by CD8+ T cells. Probably due to 
immune pressure, infected cells switch off expression of most if not all viral proteins which 
allows the virus to hibernate in cells without being detected by CD8+ T cells. This is a state of 
compromise in which the virus-infected cell does not proliferate, and the immune system fails 
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to “see” the virus. Virus-positive individuals, however, do shed virus throughout life owing to 
occasional lytic replication. This is important for virus propagation and probably also for 
virus persistence. Released viral particles could potentially infect new B cells and drive them 
into proliferation. CD8+ T cells can sense this expansion of EBV infection only once the 
infected cells started expressing latent and lytic cycle antigens.  
The finding that viral structural proteins dominate the CD4+ T cell response suggested that 
CD4+ T cells play an important role not only in the recognition of infected cells, but also in 
controlling the spreading of infection by eliminating B cells into which viral particles have 
recently gained entry. Thus, CD4+ T cells may contribute to the virus-host balance by 
limiting the number of newly infected cells and thereby reducing the reservoir from which 
EBV may reactivate.  
This balance is disturbed during states of immunodeficiency where the virus produced by a 
basal rate of lytic replication is no more controlled, resulting in unrestrained viral replication, 
re-infection of B cells and increased viral load. Adoptively-transferred T cells restore the 
virus-host balance, presumably by interfering with the virus’ life cycle at more than one stage. 
Latent antigen-specific CD8+ T cells that are known to expand upon LCL stimulation are able 
to eradicate proliferating type III latency cells. CD8+ T cells specific for immediate early and 
early lytic cycle antigens prevent virus production by cells that entered the lytic cycle. CD4+ 
T cells specific for virion proteins which also expand by LCL-stimulation eliminate newly 
infected B cells and thereby diminish the viral reservoir.  
 
Virion antigens represent promising targets for MHCII-restricted immunotherapy not only 
against PTLD but also against other virus-associated diseases 
Adoptive T cell therapy has been successfully applied to prevent or cure PTLD in BMT 
patients. Overall, the rates of PTLD in allogeneic BMT are less than 1% but can rise 
dramatically to 12% to 24% among patients in whom donor T cells are depleted from the 
marrow graft. In SOT patients, PTLD incidence ranges between 1% to 8%, depending on the 
organ transplanted and the intensity of immunosuppression (Rickinson and Kieff, 2001; 
Gottschalk et al., 2005). 
Due to the often rapid progression of PTLD, EBV-specific T cell lines have to be prepared in 
advance for patients at risk. Given the high number of transplantations performed, and the low 
percentage of transplant patients who have access to this adoptive T cell therapy, rapid 
protocols for the generation of EBV-specific T cells after PTLD manifestation are urgently 
needed. The time required to establish EBV-specific T cell lines could be dramatically 
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reduced if recently developed methods for the isolation of rare antigen-specific T cells from 
PBMC were combined with methods of antigen-independent T cell expansion in vitro. Such 
methods of T cell isolation, however, are dependent on the knowledge of the relevant T cell 
antigens and epitopes.  
The identification of a previously unrecognized point in the life cycle of EBV that is subject 
to immune control by CD4+ T cells could have important clinical implications. Induction of 
lytic replication in EBV-infected B cells followed by antiviral therapy has been proposed as a 
possible strategy for eliminating EBV-associated tumors (Daibata et al., 2005). The 
combination of virion-specific CD4+ T cell therapy with the induction of lytic replication 
may even have synergistic effects. Induction of lytic replication would eventually lead to the 
destruction of the virus-infected cell, while virion-specific T cells would prevent new cycles 
of infection. Increased virus production inside of solid tumors may also render bystander 
tumor cells susceptible to T cell attack.  
The identification of virion proteins as the prime targets of the EBV-specific CD4+ T cell 
response may facilitate the rapid generation of EBV-specific T cell lines for PTLD treatment, 
and complement the well characterized CD8+ T cell response to EBV. In addition, the 
identification of virus uncoating as a vulnerable step for the T helper cell control may fuel 
efforts to target additional EBV-associated diseases.  
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